

Case 25386

HETEROCYCLIC ANTIVIRAL COMPOUNDS

The present invention provides non-nucleoside compounds of formula **I**, and certain derivatives thereof, which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are useful as antiviral agents for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of
5 HCV replication, and for the treatment of hepatitis C infection.

Hepatitis C virus is the leading cause of chronic liver disease throughout the world. (Boyer, N. *et al.*, *J. Hepatol.* **2000** 32:98-112). Patients infected with HCV are at risk of developing cirrhosis of the liver and subsequent hepatocellular carcinoma and hence HCV is the major indication for liver transplantation.

10 HCV has been classified as a member of the virus family *Flaviviridae* that includes the genera flaviviruses, pestiviruses, and hantaviruses which includes hepatitis C viruses (Rice, C. M., *Flaviviridae: The viruses and their replication*. In: Fields Virology, Editors: B. N. Fields, D. M. Knipe and P. M. Howley, Lippincott-Raven Publishers, Philadelphia, Pa., Chapter 30, 931-959, **1996**). HCV is an enveloped virus containing a positive-sense single-stranded RNA genome of
15 approximately 9.4 kb. The viral genome consists of a highly conserved 5' untranslated region (UTR), a long open reading frame encoding a polyprotein precursor of approximately 3011 amino acids, and a short 3' UTR.

Genetic analysis of HCV has identified six main genotypes which diverge by over 30% of the DNA sequence. More than 30 subtypes have been distinguished. In the US approximately 70%
20 of infected individuals have Type 1a and 1b infection. Type 1b is the most prevalent subtype in Asia. (X. Forns and J. Bukh, *Clinics in Liver Disease* **1999** 3:693-716; J. Bukh *et al.*, *Semin. Liv. Dis.* **1995** 15:41-63). Unfortunately Type 1 infection is more resistant to therapy than either type 2 or 3 genotypes (N. N. Zein, *Clin. Microbiol. Rev.*, **2000** 13:223-235).

Viral structural proteins include a nucleocapsid core protein (C) and two envelope glycoproteins,
25 E1 and E2. HCV also encodes two proteases, a zinc-dependent metalloproteinase encoded by the NS2-NS3 region and a serine protease encoded in the NS3 region. These proteases are

required for cleavage of specific regions of the precursor polyprotein into mature peptides. The carboxyl half of nonstructural protein 5, NS5B, contains the RNA-dependent RNA polymerase. The function of the remaining nonstructural proteins, NS4A and NS4B, and that of NS5A (the amino-terminal half of nonstructural protein 5) remain unknown. It is believed that most of the non-structural proteins encoded by the HCV RNA genome are involved in RNA replication

Currently a limited number of approved therapies are available for the treatment of HCV infection. New and existing therapeutic approaches for treating HCV infection and inhibiting of HCV NS5B polymerase activity have been reviewed: R. G. Gish, *Sem. Liver. Dis.*, **1999** 19:5; Di Besceglie, A. M. and Bacon, B. R., *Scientific American*, October: **1999** 80-85; G. Lake-Bakaar, Current and Future Therapy for Chronic Hepatitis C Virus Liver Disease, *Curr. Drug Targ. Infect Dis.* **2003** 3(3):247-253; P. Hoffmann et al., Recent patent on experimental therapy for hepatitis C virus infection (1999-2002), *Exp. Opin. Ther. Patents* **2003** 13(11):1707-1723; M. P. Walker et al., Promising Candidates for the treatment of chronic hepatitis C, *Exp. Opin. Investing. Drugs* **2003** 12(8):1269-1280; S.-L. Tan et al., Hepatitis C Therapeutics: Current Status and Emerging Strategies, *Nature Rev. Drug Discov.* **2002** 1:867-881; J. Z. Wu and Z. Hong, Targeting NS5B RNA-Dependent RNA Polymerase for Anti-HCV Chemotherapy, *Curr. Drug Targ. - Infect. Dis.* **2003** 3(3):207-219.

Ribavirin (1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-[1,2,4]triazole-3-carboxylic acid amide; Virazole®) is a synthetic, non-interferon-inducing, broad-spectrum antiviral nucleoside analog. Ribavirin has in vitro activity against several DNA and RNA viruses including Flaviviridae (Gary L. Davis. *Gastroenterology* **2000** 118:S104-S114). Although, in monotherapy ribavirin reduces serum amino transferase levels to normal in 40% of patients, it does not lower serum levels of HCV-RNA. Ribavirin also exhibits significant toxicity and is known to induce anemia. Viramidine is a ribavirin prodrug converted ribavirin by adenosine deaminase to in hepatocytes. (J. Z. Wu, *Antivir. Chem. Chemother.* **2006** 17(1):33-9)

Interferons (IFNs) have been available for the treatment of chronic hepatitis for nearly a decade. IFNs are glycoproteins produced by immune cells in response to viral infection. Two distinct types of interferon are recognized: Type 1 includes several interferon alphas and one interferon beta, type 2 includes interferon gamma. Type 1 interferons are produced mainly by infected cells and protect neighboring cells from de novo infection. IFNs inhibit viral replication of many viruses, including HCV, and when used as the sole treatment for hepatitis C infection, IFN

suppresses serum HCV-RNA to undetectable levels. Additionally, IFN normalizes serum amino transferase levels. Unfortunately, the effects of IFN are temporary. Cessation of therapy results in a 70% relapse rate and only 10-15% exhibit a sustained virological response with normal serum alanine transferase levels. (Davis, Luke-Bakaar, *supra*)

- 5 One limitation of early IFN therapy was rapid clearance of the protein from the blood. Chemical derivatization of IFN with polyethyleneglycol (PEG) has resulted in proteins with substantially improved pharmacokinetic properties. PEGASYS® is a conjugate interferon α -2a and a 40 kD branched mono-methoxy PEG and PEG-INTRON® is a conjugate of interferon α -2b and a 12 kD mono-methoxy PEG. (B. A. Luxon *et al.*, *Clin. Therap.* **2002** 24(9):13631383; A. Kozłowski
10 and J. M. Harris, *J. Control. Release* **2001** 72:217-224).

Combination therapy of HCV with ribavirin and interferon- α currently is the optimal therapy for HCV. Combining ribavirin and PEG-IFN (*infra*) results in a sustained viral response (SVR) in 54-56% of patients with type 1 HCV. The SVR approaches 80% for type 2 and 3 HCV.

- (Walker, *supra*) Unfortunately, combination therapy also produces side effects which pose
15 clinical challenges. Depression, flu-like symptoms and skin reactions are associated with subcutaneous IFN- α and hemolytic anemia is associated with sustained treatment with ribavirin.

- A number of potential molecular targets for drug development as anti-HCV therapeutics have now been identified including, but not limited to, the NS2-NS3 autoprotease, the NS3 protease, the NS3 helicase and the NS5B polymerase. The RNA-dependent RNA polymerase is
20 absolutely essential for replication of the single-stranded, positive sense, RNA genome. This enzyme has elicited significant interest among medicinal chemists.

- Compounds of the present invention and their isomeric forms and pharmaceutically acceptable salts thereof are also useful in treating and preventing viral infections, in particular, hepatitis C infection, and diseases in living hosts when used in combination with each other and with other
25 biologically active agents, including but not limited to the group consisting of interferon, a pegylated interferon, ribavirin, protease inhibitors, polymerase inhibitors, small interfering RNA compounds, antisense compounds, nucleotide analogs, nucleoside analogs, immunoglobulins, immunomodulators, hepatoprotectants, anti-inflammatory agents, antibiotics, antivirals and anti-infective compounds. Such combination therapy may also comprise providing a compound
30 of the invention either concurrently or sequentially with other medicinal agents or potentiators,

such as ribavirin and related compounds, amantadine and related compounds, various interferons such as, for example, interferon-alpha, interferon-beta, interferon gamma and the like, as well as alternate forms of interferons such as pegylated interferons.

Combination therapy with of ribavirin and interferon is the current standard of care for HCV therapy. Compounds of the present invention may be administered as an additional combination therapy with interferon and ribavirin. Viramidine is a newly introduce prodrug of ribavirin which also may prove valuable.

Other interferons currently in development include albinterferon- α -2b (Albuferon), IFN-omega with DUROS, LOCTERONTM and interferon- α -2b XL. As these and other interferons reach the marketplace their use in combination therapy with compounds of the present invention is anticipated.

HCV polymerase inhibitors are another target for drug discovery and compounds in development include R-1626, R-7128, IDX184/IDX102, PF-868554 (Pfizer), VCH-759 (ViroChem), GS-9190 (Gilead), A-837093 and A-848837 (Abbot), MK-3281 (Merck), GSK949614 and GSK625433 (Glaxo), ANA598 (Anadys), VBY 708 (ViroBay).


Inhibitors of the HCV NS3 protease also have been identified as potentially useful for treatment of HCV. Protease inhibitors in clinical trials include VX-950 (Telaprevir, Vertex), SCH503034 (Brocprevir, Schering), TMC435350 (Tibotec/Medivir) and ITMN-191 (Intermune/Roche). Other protease inhibitors in earlier stages of development include MK7009 (Merck), BMS-790052 (Bristol Myers Squibb), VBY-376 (Virobay), IDXSCA/IDXSCB (Idenix), BI12202 (Boehringer), VX-500 (Vertex), PHX1766 Phenomix).

Other targets for anti-HCV therapy under investigation include cyclophilin inhibitors which inhibit RNA binding to NS5b, nitazoxanide, Celgosivir (Migenix), an inhibitor of α -glucosidase-1, caspase inhibitors, Toll-like receptor agonists and immunostimulants such as Zadaxin (SciClone).

There is currently no preventive treatment of Hepatitis C virus (HCV) and currently approved therapies, which exist only against HCV, are limited. Design and development of new pharmaceutical compounds is essential.

-5-

The present invention provides a compound according to formula **I**, or a pharmaceutically acceptable salt thereof, wherein:

**I**

A is a heteroaryl radical selected from the group consisting of 3-oxo-3,4-dihydro-pyrazin-2-yl, 3-oxo-2,3-dihydro-pyridazin-4-yl, 6-oxo-1,6-dihydro-pyrimidin-5-yl, 6-oxo-1,6-dihydro-[1,2,4]triazin-5-yl, 2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl and 4,6-dioxo-1,4,5,6-tetrahydro-pyrimidin-5-yl said heteroaryl being optionally substituted by halogen, C₁₋₆ alkyl, C₁₋₃ haloalkyl, C₁₋₃ dialkylamino or C₁₋₆ alkoxy.

R¹ is hydrogen, hydroxy, C₁₋₃ hydroxyalkyl, COX or cyano.

- 10 **R**² is (a) -[C(**R**⁶)₂]_p-**Ar**¹, (b) **CR**^{7a}=**CR**^{7b}**Ar**¹, (c) naphthyl optionally substituted by one to three groups independently selected from the group consisting of C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_n**NR**^c**R**^d, cyano, C₁₋₆ alkoxycarbonyl, and carboxyl (d) -**NR**⁵**COAr**¹ or (e) **CONR**⁵**Ar**¹.

- 15 **R**³ alone is hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, or halogen or **R**³ and **R**^{4a} together are CH₂-O and together with atoms to which they are attached form a 2,3-dihydrobenzofuran.

- R**^{4a}, **R**^{4b} and **R**^{4c} (i) when taken independently are selected independently from C₁₋₃ alkyl, C₁₋₂ alkoxy, C₁₋₂ fluoroalkyl, hydroxy or halogen or (ii) when taken together, **R**^{4a} and **R**^{4b} together are C₂₋₄ methylene and **R**^{4c} is C₁₋₃ alkyl, C₁₋₂ alkoxy, C₁₋₂ fluoroalkyl or halogen, or (iii) either **R**⁸ or 20 **R**³ and **R**^{4a} together are CH₂-O and together with atoms to which they are attached form a 2,3-dihydro-benzofuran and **R**^{4b} and **R**^{4c} are C₁₋₃ alkyl, or (iv) **R**^{4a} and **R**^{4b} together are ethylene and **R**^{4c} is hydrogen, or (v) **R**^{4a}, **R**^{4b} and **R**^{4c} together with the carbon to which they are attached are C₁₋₆ fluoroalkyl.

- 25 **R**⁸ is hydrogen, fluorine or **R**⁸ and **R**^{4a} together are CH₂-O and together with atoms to which they are attached form a 2,3-dihydrobenzofuran.

R⁵ is hydrogen or C₁₋₆ alkyl.

R^6 is independently in each occurrence hydrogen, C_{1-6} alkyl, carboxy, C_{1-6} alkoxy carbonyl or C_{1-6} hydroxyalkyl.

R^{7a} and R^{7b} are independently hydrogen or C_{1-6} alkyl.

5 Ar^1 is phenyl or pyridinyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, halogen, $(CH_2)_nNR^cR^d$, cyano, C_{1-6} alkoxy carbonyl, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl and carboxyl.

10 R^c and R^d are independently in hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} acyl, C_{1-6} sulfonyl, sulfamoyl C_{1-3} alkylsulfamoyl, C_{1-3} dialkylsulfamoyl, carbamoyl, C_{1-3} alkylcarbamoyl, C_{1-3} dialkylcarbamoyl.

X is OH, C_{1-6} alkoxy or NR^eR^f .

R^e and R^f are independently hydrogen or C_{1-6} alkyl.

n is zero or 1.

p is zero to three; or pharmaceutically acceptable salts thereof.

15 Object of the present invention are medicaments based on compounds according to the formula I in the control and prevention of Hepatitis C Virus (HCV) infections, and for the inhibition of replication of HCV in a cell. Medicaments according to the invention can comprise compounds according to formula I alone or in combination with other antiviral compounds or immunomodulators.

20 The present invention also provides a method for treating a disease a Hepatitis C Virus (HCV) virus infection by administering a therapeutically effective quantity of a compound according to formula I to a patient in need thereof. The compound can be administered alone or co-administered with other antiviral compounds or immunomodulators.

25 The present invention also provides a method for inhibiting replication of HCV in a cell by administering a compound according to formula I in an amount effective to inhibit HCV.

The present invention also provides a pharmaceutical composition comprising a compound according to formula I and at least one pharmaceutically acceptable carrier, diluent or excipient.

The phrase "a" or "an" entity as used herein refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound. As such, the terms "a" (or "an"), "one or more", and "at least one" can be used interchangeably herein.


5 The phrase "as defined herein above" refers to the broadest definition for each group provided or the broadest claim. In all other embodiments provided below, substituents which can be present in each embodiment and which are not explicitly defined retain the broadest definition provided above.

As used in this specification, whether in a transitional phrase or in the body of the claim, the terms "comprise(s)" and "comprising" are to be interpreted as having an open-ended meaning.
10 That is, the terms are to be interpreted synonymously with the phrases "having at least" or "including at least". When used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound or composition, the term "comprising" means that the compound or composition includes at least the recited features or components, but may also include additional
15 features or components.

The term "independently" is used herein to indicate that a variable is applied in any one instance without regard to the presence or absence of a variable having that same or a different definition within the same compound. Thus, in a compound in which R" appears twice and is defined as "independently carbon or nitrogen", both R"s can be carbon, both R"s can be nitrogen, or one R"
20 can be carbon and the other nitrogen.

When any variable (e.g., R¹, R^{4a}, Ar, X¹ or Het) occurs more than one time in any moiety or formula depicting and describing compounds employed or claimed in the present invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such compounds result in
25 stable compounds.

The symbols "*" at the end of a bond or "-----" drawn through a bond each refer to the point of attachment of a functional group or other chemical moiety to the rest of the molecule of which it is a part. Thus, for example:



A bond drawn into ring system (as opposed to connected at a distinct vertex) indicates that the bond may be attached to any of the suitable ring atoms.

The term "optional" or "optionally" as used herein means that a subsequently described event or
 5 circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optionally substituted" means that the optionally substituted moiety may incorporate a hydrogen or a substituent.

The term "about" is used herein to mean approximately, in the region of, roughly, or around.

10 When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 20%.

As used herein, the recitation of a numerical range for a variable is intended to convey that the
 15 invention may be practiced with the variable equal to any of the values within that range. Thus, for a variable which is inherently discrete, the variable can be equal to any integer value of the numerical range, including the end-points of the range. Similarly, for a variable which is inherently continuous, the variable can be equal to any real value of the numerical range, including the end-points of the range. As an example, a variable which is described as having
 20 values between 0 and 2, can be 0, 1 or 2 for variables which are inherently discrete, and can be 0.0, 0.1, 0.01, 0.001, or any other real value for variables which are inherently continuous.

Compounds of formula **I** exhibit tautomerism. Tautomeric compounds can exist as two or more interconvertible species. Prototropic tautomers result from the migration of a covalently bonded hydrogen atom between two atoms. Tautomers generally exist in equilibrium and attempts to
 25 isolate an individual tautomers usually produce a mixture whose chemical and physical properties are consistent with a mixture of compounds. The position of the equilibrium is dependent on chemical features within the molecule. For example, in many aliphatic aldehydes and ketones, such as acetaldehyde, the keto form predominates while; in phenols, the enol form predominates. Common prototropic tautomers include keto/enol ($-\text{C(=O)}-\text{CH}- \rightleftharpoons -\text{C}(\text{-OH})=\text{CH}-$

), amide/imidic acid ($\text{-C(=O)-NH-} \rightleftharpoons \text{-C(-OH)=N-}$) and amidine ($\text{-C(=NR)-NH-} \rightleftharpoons \text{-C(-NHR)=N-}$) tautomers. The latter two are particularly common in heteroaryl and heterocyclic rings and the present invention encompasses all tautomeric forms of the compounds.

It will be appreciated by the skilled artisan that some of the compounds of formula **I** may contain one or more chiral centers and therefore exist in two or more stereoisomeric forms. The racemates of these isomers, the individual isomers and mixtures enriched in one enantiomer, as well as diastereomers when there are two chiral centers, and mixtures partially enriched with specific diastereomers are within the scope of the present invention. It will be further appreciated by the skilled artisan that substitution of the tropane ring can be in either *endo*- or *exo*-configuration, and the present invention covers both configurations. The present invention includes all the individual stereoisomers (e.g. enantiomers), racemic mixtures or partially resolved mixtures of the compounds of formulae **I** and, where appropriate, the individual tautomeric forms thereof.


The racemates can be used as such or can be resolved into their individual isomers. The resolution can afford stereochemically pure compounds or mixtures enriched in one or more isomers. Methods for separation of isomers are well known (*cf.* Allinger N. L. and Eliel E. L. in "*Topics in Stereochemistry*", Vol. 6, Wiley Interscience, **1971**) and include physical methods such as chromatography using a chiral adsorbent. Individual isomers can be prepared in chiral form from chiral precursors. Alternatively individual isomers can be separated chemically from a mixture by forming diastereomeric salts with a chiral acid, such as the individual enantiomers of 10-camphorsulfonic acid, camphoric acid, .alpha.-bromocamphoric acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, and the like, fractionally crystallizing the salts, and then freeing one or both of the resolved bases, optionally repeating the process, so as obtain either or both substantially free of the other; i.e., in a form having an optical purity of >95%. Alternatively the racemates can be covalently linked to a chiral compound (auxillary) to produce diastereomers which can be separated by chromatography or by fractional crystallization after which time the chiral auxiliary is chemically removed to afford the pure enantiomers.

When compounds of formula **I** contain a basic center and suitable acid addition salts may be formed from acids which form non-toxic salts. Examples of salts of inorganic acids include the hydrochloride, hydrobromide, hydroiodide, chloride, bromide, iodide, sulphate, bisulphate,

nitrate, phosphate, hydrogen phosphate. Examples of salts of organic acids include acetate, fumarate, pamoate, aspartate, besylate, carbonate, bicarbonate, camsylate, D and L-lactate, D and L-tartrate, esylate, mesylate, malonate, orotate, gluceptate, methylsulphate, stearate, glucuronate, 2-napsylate, tosylate, hibenzone, nicotinate, isethionate, malate, maleate, citrate, gluconate, succinate, saccharate, benzoate, esylate, and pamoate salts. For a review on suitable salts see Berge *et al*, *J. Pharm. Sci.*, **1977** 66:1-19 and G. S. Paulekuhn *et al*. *J. Med. Chem.* **2007** 50:6665.

Technical and scientific terms used herein have the meaning commonly understood by one of skill in the art to which the present invention pertains, unless otherwise defined. Reference is made herein to various methodologies and materials known to those of skill in the art. Standard reference works setting forth the general principles of pharmacology include Goodman and Gilman's *The Pharmacological Basis of Therapeutics*, 10th Ed., McGraw Hill Companies Inc., New York (**2001**). The starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references. Materials, reagents and the like to which reference are made in the following description and examples are obtainable from commercial sources, unless otherwise noted. General synthetic procedures have been described in treatise such as *Fieser and Fieser's Reagents for Organic Synthesis*; Wiley & Sons: New York, Volumes 1-21; R. C. LaRock, *Comprehensive Organic Transformations*, 2nd edition Wiley-VCH, New York **1999**; *Comprehensive Organic Synthesis*, B. Trost and I. Fleming (Eds.) vol. 1-9 Pergamon, Oxford, **1991**; *Comprehensive Heterocyclic Chemistry*, A. R. Katritzky and C. W. Rees (Eds) Pergamon, Oxford **1984**, vol. 1-9; *Comprehensive Heterocyclic Chemistry II*, A. R. Katritzky and C. W. Rees (Eds) Pergamon, Oxford **1996**, vol. 1-11; and *Organic Reactions*, Wiley & Sons: New York, **1991**, Volumes 1-40 and will be familiar to those skilled in the art.

In an embodiment of the present invention there is provided a compound according to formula I



[0001]

I

wherein

A is a heteroaryl radical selected from the group consisting of

3-oxo-3,4-dihydro-pyrazin-2-yl,

3-oxo-2,3-dihydro-pyridazin-4-yl,

5 6-oxo-1,6-dihydro-pyrimidin-5-yl,

6-oxo-1,6-dihydro-[1,2,4]triazin-5-yl and

2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl said heteroaryl radical optionally substituted by halogen, C₁₋₆ alkyl, C₁₋₃ haloalkyl, C₁₋₆ alkoxy or benzyloxy.

R¹ is hydrogen, hydroxy, C₁₋₃ hydroxyalkyl, COX or cyano.

10 **R**² is (a) -[C(**R**⁶)₂]_p-**Ar**¹, (b) **CR**^{7a}=**CR**^{7b}**Ar**¹; (c) -NR⁵CO**Ar**¹ or (d) CONR⁵**Ar**¹.

R³ is hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, halogen or

R³ and **R**^{4a} together are CH₂-O and together with atoms to which they are attached form a 2,3-dihydrobenzofuran.

R^{4a}, **R**^{4b} and **R**^{4c}

15 (i) when taken independently are selected independently from C₁₋₃ alkyl, C₁₋₂ alkoxy, C₁₋₂ fluoroalkyl, hydroxy or halogen or

(ii) when taken together, **R**^{4a} and **R**^{4b} together are C₂₋₄ methylene and **R**^{4c} is C₁₋₃ alkyl, C₁₋₂ alkoxy, C₁₋₂ fluoroalkyl or halogen, or

(iii) either **R**⁸ or **R**³ and **R**^{4a} together are CH₂-O and together with atoms to which they are
20 attached for a 2,3-dihydro-benzofuran and **R**^{4b} and **R**^{4c} are C₁₋₃ alkyl.

R⁸ is hydrogen, fluorine or **R**⁸ and **R**^{4a} together are CH₂-O and together with atoms to which they are attached form a 2,3-dihydrobenzofuran.

R⁵ is hydrogen or C₁₋₆ alkyl.

R⁶ is independently in each occurrence hydrogen, C₁₋₆ alkyl, carboxy, C₁₋₆ alkoxy, carbonyl or C₁₋₆ hydroxyalkyl.
25

R^{7a} and **R**^{7b} are independently hydrogen or C₁₋₆ alkyl.

Ar¹ is phenyl or pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_nNR^c**R**^d, cyano, C₁₋₆ alkoxy, carbonyl,

carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, carboxyl, SO₂NH₂, C₁₋₆ alkylsulfinyl and C₁₋₆ alkylsulfonyl.

R^c and **R^d** are independently in hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ acyl, C₁₋₆ sulfonyl, C₁₋₆ haloalkylsulfonyl, C₃₋₇ cycloalkylsulfonyl, C₃₋₇ cycloalkyl-C₁₋₃ alkyl-sulfonyl, C₁₋₆ alkoxy-C₁₋₆ alkylsulfonyl, sulfamoyl, C₁₋₃ alkylsulfamoyl, C₁₋₃ dialkylsulfamoyl, carbamoyl, C₁₋₃ alkylcarbamoyl or C₁₋₃ dialkylcarbamoyl.

X is OH, C₁₋₆ alkoxy or NR^eR^f.

R^e and **R^f** are independently hydrogen or C₁₋₆ alkyl.

n is zero or 1.

10 **p** is zero to three or

a pharmaceutically acceptable salt thereof.

In one embodiment of the present invention there is provided a compound according to formula I where A, R¹, R², R³, R^{4a}, R^{4b}, R^{4c}, R⁵, R⁶, R^{7a}, R^{7b}, R⁸, Ar¹, R^c, R^d, R^e, R^f, X, n and p are as defined hereinabove. In all other embodiments provided below, substituents which can be present in each embodiment and which are not explicitly defined retain the broadest definition provided in the Summary of the Invention.

In a another embodiment of the present invention there is provided a compound according to formula I wherein A is 3-oxo-2,3-dihydro-pyridazin-4-yl.

20 In a another embodiment of the present invention there is provided a compound according to formula I wherein A is 3-oxo-2,3-dihydro-pyridazin-4-yl; **R¹** is hydrogen or hydroxy; **R²** is (a) -[C(R⁶)₂]_p-Ar¹, (b) CR^{7a}=CR^{7b}Ar¹ or (c) -NR⁵COAr¹; **R^{4a}**, **R^{4b}** and **R^{4c}** are independently C₁₋₃ alkyl; **R⁶**, **R^{7a}** and **R^{7b}** are hydrogen; and **Ar¹** is phenyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_nNR^cR^d.

25 In a another embodiment of the present invention there is provided a compound according to formula I wherein A is 3-oxo-2,3-dihydro-pyridazin-4-yl; **R¹** is hydrogen or hydroxy; **R²** is (a) -[C(R⁶)₂]_p-Ar¹, (b) CR^{7a}=CR^{7b}Ar¹ or (c) -NR⁵COAr¹; either **R⁸** or **R³** and **R^{4a}** together are CH₂-O and together with atoms to which they are attached for a 2,3-dihydro-benzofuran and **R^{4b}** and **R^{4c}** are C₁₋₃ alkyl; **R⁶**, **R^{7a}** and **R^{7b}** are hydrogen; and **Ar¹** is phenyl or pyridinyl either optionally

independently substituted with one to three substituents selected from the group consisting of hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_nNR^cR^d.

In a another embodiment of the present invention there is provided a compound according to formula **I** wherein **A** is 3-oxo-2,3-dihydro-pyridazin-4-yl; **R**¹ is hydrogen; **R**² is CR^{7a}=CR^{7b}Ar¹; **R**^{4a}, **R**^{4b} and **R**^{4c} are independently C₁₋₃ alkyl; **R**⁶, **R**^{7a} and **R**^{7b} are hydrogen; **Ar**¹ is phenyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_nNR^cR^d.

In a another embodiment of the present invention there is provided a compound according to formula **I** wherein **A** is 3-oxo-2,3-dihydro-pyridazin-4-yl; **R**¹ is hydrogen; **R**² is (a) -[C(R⁶)₂]_p-Ar¹ or (b) CR^{7a}=CR^{7b}Ar¹; **R**^{4a}, **R**^{4b} and **R**^{4c} are independently C₁₋₃ alkyl; **R**⁶, **R**^{7a} and **R**^{7b} are hydrogen; and **Ar**¹ is phenyl substituted at least by (CH₂)_nNR^cR^d; **R**^c is hydrogen or C₁₋₃ alkyl and **R**^d is C₁₋₆ alkylsulfonyl.

In a another embodiment of the present invention there is provided a compound according to formula **I** wherein **A** is 3-oxo-2,3-dihydro -pyridazin -4-yl; **R**² is -NR⁵COAr¹; **Ar**¹ is phenyl substituted at least by (CH₂)_nNR^cR^d, **R**^c is hydrogen or C₁₋₃ alkyl and **R**^d is C₁₋₆ alkylsulfonyl.

In a another embodiment of the present invention there is provided a compound according to formula **I** wherein **A** is 3-oxo-3,4-dihydro-pyrazin-2-yl.

In a another embodiment of the present invention there is provided a compound according to the formula **I** wherein **A** is 3-oxo-3,4-dihydro-pyrazin-2-yl; **R**¹ is hydrogen or hydroxy; **R**² is (a) -[C(R⁶)₂]_p-Ar¹, (b) CR^{7a}=CR^{7b}Ar¹ or (c) -NR⁵COAr¹; **R**^{4a}, **R**^{4b} and **R**^{4c} are independently C₁₋₃ alkyl; **R**⁶, **R**^{7a} and **R**^{7b} are hydrogen; and **Ar**¹ is phenyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_nNR^cR^d.

In a another embodiment of the present invention there is provided a compound according to the formula **I** wherein **A** is 3-oxo-3,4-dihydro-pyrazin-2-yl; **R**¹ is hydrogen; **R**² is CR^{7a}=CR^{7b}Ar¹; **R**^{4a}, **R**^{4b} and **R**^{4c} are independently C₁₋₃ alkyl; **R**⁶, **R**^{7a} and **R**^{7b} are hydrogen; and **Ar**¹ is phenyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_nNR^cR^d.

In a tenth embodiment of the present invention there is provided a compound according to the formula **I** wherein **A** is 3-oxo-3,4-dihydro-pyrazin-2-yl; **R**¹ is hydrogen or hydroxy; **R**² is (b) $\text{CR}^{7a}=\text{CR}^{7b}\text{Ar}^1$; **R**^{4a}, **R**^{4b} and **R**^{4c} are independently C₁₋₃ alkyl; **R**⁶, **R**^{7a} and **R**^{7b} are hydrogen; **Ar**¹ is phenyl substituted at least by (CH₂)_nNR^cR^d, **R**^c is hydrogen or C₁₋₃ alkyl and **R**^d is C₁₋₆ alkylsulfonyl.

In another embodiment of the present invention there is provided a compound according to the formula **I** wherein **A** is 3-oxo-3,4-dihydro-pyrazin-2-yl; **R**¹ is hydrogen or hydroxy; **R**² is (c) -NR⁵COAr¹; **R**^{4a}, **R**^{4b} and **R**^{4c} are independently C₁₋₃ alkyl; **R**⁶ is hydrogen; **Ar**¹ is phenyl substituted at least by (CH₂)_nNR^cR^d, **R**^c is hydrogen or C₁₋₃ alkyl and **R**^d is C₁₋₆ alkylsulfonyl.

10 In a another embodiment of the present invention there is provided a compound according to formula **I** wherein **A** is optionally substituted 6-oxo-1,6-dihydro-pyrimidin-5-yl.

In another embodiment of the present invention there is provided a compound according to formula **I** wherein **A** is optionally substituted 6-oxo-1,6-dihydro-pyrimidin-5-yl and **R**² is optionally substituted naphthyl.

15 In another embodiment of the present invention there is provided a compound according to formula **I** wherein **A** is optionally substituted 6-oxo-1,6-dihydro-pyrimidin-5-yl; **R**² is optionally substituted 6-((CH₂)_nNR^cR^d)-naphth-2-yl, **R**^c is hydrogen or C₁₋₃ alkyl and **R**^d is C₁₋₆ alkylsulfonyl naphthyl.

20 In another embodiment of the present invention there is provided a compound according to formula **I** wherein **A** is optionally substituted 6-oxo-1,6-dihydro-pyrimidin-5-yl, **R**^{4a}, **R**^{4b} and **R**^{4c} are independently C₁₋₃ alkyl; **R**² is optionally substituted 6-((CH₂)_nNR^cR^d)-naphth-2-yl, **R**^c is hydrogen or C₁₋₃ alkyl and **R**^d is C₁₋₆ alkylsulfonyl naphthyl.

25 In another embodiment of the present invention there is provided a compound according to formula **I** wherein **A** is optionally substituted 6-oxo-1,6-dihydro-pyrimidin-5-yl, **R**⁸ or **R**³ and **R**^{4a} together are CH₂-O and together with atoms to which they are attached for a 2,3-dihydro-benzofuran; **R**² is optionally substituted 6-((CH₂)_nNR^cR^d)-naphth-2-yl, **R**^c is hydrogen or C₁₋₃ alkyl and **R**^d is C₁₋₆ alkylsulfonyl naphthyl.

In another embodiment of the present invention there is provided a compound according to formula **I** wherein **A** is optionally substituted 6-oxo-1,6-dihydro-pyrimidin-5-yl, either **R**^{4a}, **R**^{4b} and **R**^{4c} are fluoro or **R**^{4a} is trifluoromethyl and **R**^{4b} and **R**^{4c} are hydrogen; **R**² is optionally substituted 6-((CH₂)_nNR^cR^d)-naphth-2-yl, **R**^c is hydrogen or C₁₋₃ alkyl and **R**^d is C₁₋₆ alkylsulfonyl naphthyl.

In another embodiment of the present invention there is provided a compound according to the formula **I** wherein **A** is optionally substituted 6-oxo-1,6-dihydro-pyrimidin-5-yl; **R**¹ is hydrogen or hydroxy; **R**² is (a) CR^{7a}=CR^{7b}Ar¹ or (b) -NR⁵COAr¹; **R**^{4a}, **R**^{4b} and **R**^{4c} are independently C₁₋₃ alkyl; **R**⁶, **R**^{7a} and **R**^{7b} are hydrogen; and Ar¹ is phenyl or pyridinyl either optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_nNR^cR^d.

In another embodiment of the present invention there is provided a compound according to formula **I** wherein **A** is 6-oxo-1,6-dihydro-[1,2,4]triazin-5-yl.

In another embodiment of the present invention there is provided a compound according to the formula **I** wherein **A** is optionally substituted 6-oxo-1,6-dihydro-[1,2,4]triazin-5-yl; **R**¹ is hydrogen; **R**² is CR^{7a}=CR^{7b}Ar¹; **R**^{4a}, **R**^{4b} and **R**^{4c} are independently C₁₋₃ alkyl; **R**⁶, **R**^{7a} and **R**^{7b} are hydrogen; and Ar¹ is phenyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_nNR^cR^d.

In another embodiment of the present invention there is provided a compound according to the formula **I** wherein **A** is optionally substituted 6-oxo-1,6-dihydro-[1,2,4]triazin-5-yl; **R**¹ is hydrogen or hydroxy; **R**² is optionally substituted naphthyl; **R**^{4a}, **R**^{4b} and **R**^{4c} are independently C₁₋₃ alkyl; **R**⁶, **R**^{7a} and **R**^{7b} are hydrogen; and Ar¹ is phenyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_nNR^cR^d.

In another embodiment of the present invention there is provided a compound according to formula **I** wherein **A** is 2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl.

In another embodiment of the present invention there is provided a compound according to the formula **I** wherein **A** is optionally substituted 2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl; **R**¹ is

hydrogen; R^2 is $CR^{7a}=CR^{7b}Ar^1$; R^{4a} , R^{4b} and R^{4c} are independently C_{1-3} alkyl; R^6 , R^{7a} and R^{7b} are hydrogen; and Ar^1 is phenyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, halogen, $(CH_2)_nNR^cR^d$.

- 5 In another embodiment of the present invention there is provided a compound according to formula I wherein A is 4,6-dioxo-2-methyl-1,4,5,6-tetrahydro-pyrimidin-5-yl.

In another embodiment of the present invention there is provided a compound according to the formula I wherein A is optionally substituted 4,6-dioxo-2-methyl-1,4,5,6-tetrahydro-pyrimidin-5-ylw; R^1 is hydrogen; R^2 is $CR^{7a}=CR^{7b}Ar^1$; R^{4a} , R^{4b} and R^{4c} are independently C_{1-3} alkyl; R^6 , R^{7a} and R^{7b} are hydrogen; and Ar^1 is phenyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, halogen, $(CH_2)_nNR^cR^d$.

10

In another embodiment of the present invention there is provided a compound according to formula I where A, R^1 , R^2 , R^3 , R^{4a} , R^{4b} , R^{4c} , R^5 , R^6 , R^{7a} , R^{7b} , R^8 , Ar^1 , R^a , R^b , R^c , R^d , R^e , R^f , X, n and p are as defined hereinabove which compound is selected from compounds I-1 to I-43 in TABLE 1.

15

In a further embodiment of the present invention there is provided a compound of formula I, wherein A, R^1 , R^2 , R^3 , R^{4a} , R^{4b} , R^{4c} , R^5 , R^6 , R^{7a} , R^{7b} , R^8 , Ar^1 , R^a , R^b , R^c , R^d , R^e , R^f , X, n and p are as defined hereinabove for the manufacture of a medicament useful in the treatment of a HCV infection.

20

In a further embodiment of the present invention there is provided a compound of formula I, wherein A, R^1 , R^2 , R^3 , R^{4a} , R^{4b} , R^{4c} , R^5 , R^6 , R^{7a} , R^{7b} , R^8 , Ar^1 , R^a , R^b , R^c , R^d , R^e , R^f , X, n and p are as defined hereinabove alone of in combination with at least one immune system modulator and/or at least one antiviral agent that inhibits replication of HCV for the manufacture of a medicament useful in the treatment of a HCV infection.

25

In a further embodiment of the present invention there is provided a compound of formula I, wherein A, R^1 , R^2 , R^3 , R^{4a} , R^{4b} , R^{4c} , R^5 , R^6 , R^{7a} , R^{7b} , R^8 , Ar^1 , R^a , R^b , R^c , R^d , R^e , R^f , X, n and p are as defined hereinabove alone of in combination with at least one immune system modulator selected from interferon, a chemically derivatized interferon, interleukin, tumor necrosis factor

or colony stimulating factor for the manufacture of a medicament useful in the treatment of a HCV infection..

In a further embodiment of the present invention there is provided a compound of formula I, wherein **A**, **R¹**, **R²**, **R³**, **R^{4a}**, **R^{4b}**, **R^{4c}**, **R⁵**, **R⁶**, **R^{7a}**, **R^{7b}**, **R⁸**, **Ar¹**, **R^a**, **R^b**, **R^c**, **R^d**, **R^e**, **R^f**, **X**, **n** and **p** are as defined hereinabove alone or in combination with and an interferon or a chemically derivatized interferon for the manufacture of a medicament useful in the treatment of a HCV infection..

In another embodiment of the present invention there is provided a method of treating a HCV infection in a patient in need thereof comprising administering a therapeutically effective amount of a compound according to formula I wherein **A**, **R¹**, **R²**, **R³**, **R^{4a}**, **R^{4b}**, **R^{4c}**, **R⁵**, **R⁶**, **R^{7a}**, **R^{7b}**, **R⁸**, **Ar¹**, **R^c**, **R^d**, **R^e**, **R^f**, **X**, **n** and **p** are as defined hereinabove.

In another embodiment of the present invention there is provide a method of treating a HCV infection in a patient in need thereof comprising co-administering a therapeutically effective amount of a compound according to formula I wherein **A**, **R¹**, **R²**, **R³**, **R^{4a}**, **R^{4b}**, **R^{4c}**, **R⁵**, **R⁶**, **R^{7a}**, **R^{7b}**, **R⁸**, **Ar¹**, **R^c**, **R^d**, **R^e**, **R^f**, **X**, **n** and **p** are as defined herein above and at least one immune system modulator and/or at least one antiviral agent that inhibits replication of HCV.

In another -second embodiment of the present invention there is provide a method of treating a disease caused by HCV in a patient in need thereof comprising co-administering a therapeutically effective amount of a compound according to formula I wherein **A**, **R¹**, **R²**, **R³**, **R^{4a}**, **R^{4b}**, **R^{4c}**, **R⁵**, **R⁶**, **R^{7a}**, **R^{7b}**, **R⁸**, **Ar¹**, **R^c**, **R^d**, **R^e**, **R^f**, **X**, **n** and **p** are as defined herein above and at least one immune system modulator selected from interferon, a chemically derivatized interferon, interleukin, tumor necrosis factor or colony stimulating factor.

In another embodiment of the present invention there is provide a method of treating a HCV infection in a patient in need thereof comprising co-administering a therapeutically effective amount of a compound according to formula I wherein **A**, **R¹**, **R²**, **R³**, **R^{4a}**, **R^{4b}**, **R^{4c}**, **R⁵**, **R⁶**, **R^{7a}**, **R^{7b}**, **R⁸**, **Ar¹**, **R^c**, **R^d**, **R^e**, **R^f**, **X**, **n** and **p** are as defined herein above and an interferon or a chemically derivatized interferon.

In another embodiment of the present invention there is provide a method of treating a HCV infection in a patient in need thereof comprising co-administering a therapeutically effective

amount of a compound according to formula **I** wherein **A**, **R¹**, **R²**, **R³**, **R^{4a}**, **R^{4b}**, **R^{4c}**, **R⁵**, **R⁶**, **R^{7a}**, **R^{7b}**, **R⁸**, **Ar¹**, **R^c**, **R^d**, **R^e**, **R^f**, **X**, **n** and **p** are as defined herein above and at least one other antiviral compound selected from the group consisting of a HCV protease inhibitor, another HCV polymerase inhibitor, a HCV helicase inhibitor, a HCV primase inhibitor and a HCV fusion inhibitor.

In another embodiment of the present invention there is provided a method for inhibiting replication of HCV in a cell by delivering a compound according to formula **I** wherein **A**, **R¹**, **R²**, **R³**, **R^{4a}**, **R^{4b}**, **R^{4c}**, **R⁵**, **R⁶**, **R^{7a}**, **R^{7b}**, **R⁸**, **Ar¹**, **R^c**, **R^d**, **R^e**, **R^f**, **X**, **n** and **p** are as defined herein above.

- 10 In another embodiment of the present invention there is provided a composition comprising a compound according to formula **I** wherein **A**, **R¹**, **R²**, **R³**, **R^{4a}**, **R^{4b}**, **R^{4c}**, **R⁵**, **R⁶**, **R^{7a}**, **R^{7b}**, **R⁸**, **Ar¹**, **R^c**, **R^d**, **R^e**, **R^f**, **X**, **n** and **p** are as defined herein above admixed with at least one pharmaceutically acceptable carrier, diluent or excipient.

The term “alkyl” as used herein without further limitation alone or in combination with other groups, denotes an unbranched or branched chain, saturated, monovalent hydrocarbon residue containing 1 to 10 carbon atoms. The term “lower alkyl” denotes a straight or branched chain hydrocarbon residue containing 1 to 6 carbon atoms. “C₁₋₆ alkyl” as used herein refers to an alkyl composed of 1 to 6 carbons. Examples of alkyl groups include, but are not limited to, lower alkyl groups include methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *tert*-butyl, neopentyl, hexyl, and octyl.

The definitions described herein may be appended to form chemically-relevant combinations, such as “heteroalkylaryl,” “haloalkylheteroaryl,” “arylalkylheterocyclyl,” “alkylcarbonyl,” “alkoxyalkyl,” and the like. When the term “alkyl” is used as a suffix following another term, as in “phenylalkyl,” or “hydroxyalkyl,” this is intended to refer to an alkyl group, as defined above, being substituted with one to two substituents selected from the other specifically-named group. Thus, for example, “phenylalkyl” refers to an alkyl group having one to two phenyl substituents, and thus includes benzyl, phenylethyl, and biphenyl. An “alkylaminoalkyl” is an alkyl group having one to two alkylamino substituents. “Hydroxyalkyl” includes 2-hydroxyethyl, 2-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 2,3-dihydroxybutyl, 2-(hydroxymethyl), 3-hydroxypropyl, and so forth. Accordingly, as used herein, the term

"hydroxyalkyl" is used to define a subset of heteroalkyl groups defined below. The term - (ar)alkyl refers to either an unsubstituted alkyl or an aralkyl group. The term (hetero)aryl or (hetero)aryl refers to either an aryl or a heteroaryl group.

The term "alkylene" as used herein denotes a divalent saturated linear hydrocarbon radical of 1 to 10 carbon atoms (*e.g.*, $(\text{CH}_2)_n$) or a branched saturated divalent hydrocarbon radical of 2 to 10 carbon atoms (*e.g.*, -CHMe- or -CH₂CH(*i*-Pr)CH₂-), unless otherwise indicated. C₀₋₄ alkylene refers to a linear or branched saturated divalent hydrocarbon radical comprising 1-4 carbon atoms or, in the case of C₀, the alkylene radical is omitted. Except in the case of methylene, the open valences of an alkylene group are not attached to the same atom. Examples of alkylene radicals include, but are not limited to, methylene, ethylene, propylene, 2-methyl-propylene, 1,1-dimethyl-ethylene, butylene, 2-ethylbutylene.

The term "alkoxy" as used herein means an -O-alkyl group, wherein alkyl is as defined above such as methoxy, ethoxy, *n*-propyloxy, *i*-propyloxy, *n*-butyloxy, *i*-butyloxy, *t*-butyloxy, pentyloxy, hexyloxy, including their isomers. "Lower alkoxy" as used herein denotes an alkoxy group with a "lower alkyl" group as previously defined. "C₁₋₁₀ alkoxy" as used herein refers to an -O-alkyl wherein alkyl is C₁₋₁₀.

The term "haloalkyl" as used herein denotes a unbranched or branched chain alkyl group as defined above wherein 1, 2, 3 or more hydrogen atoms are substituted by a halogen. Examples are 1-fluoromethyl, 1-chloromethyl, 1-bromomethyl, 1-iodomethyl, difluoromethyl, trifluoromethyl, trichloromethyl, 1-fluoroethyl, 1-chloroethyl, 1,2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2,2-dichloroethyl, 3-bromopropyl or 2,2,2-trifluoroethyl. The term "fluoroalkyl" as used herein refers to a haloalkyl moiety wherein fluorine is the halogen.

The term "halogen" or "halo" as used herein means fluorine, chlorine, bromine, or iodine.

The terms "hydroxyalkyl" and "alkoxyalkyl" as used herein denotes alkyl radical as herein defined wherein one to three hydrogen atoms on different carbon atoms is/are replaced by hydroxyl or alkoxy groups respectively. A C₁₋₃ alkoxy-C₁₋₆ alkyl moiety refers to a C₁₋₆ alkyl substituent in which 1 to 3 hydrogen atoms are replaced by a C₁₋₃ alkoxy and the point of attachment of the alkoxy is the oxygen atom.

The terms "alkoxycarbonyl" and "aryloxycarbonyl" as used herein denotes a group of formula -C(=O)OR wherein R is alkyl or aryl respectively and alkyl and aryl are as defined herein.

The term "cyano" as used herein refers to a carbon linked to a nitrogen by a triple bond, i.e., -C≡N. The term "nitro" as used herein refers to a group -NO₂. The term "carboxy" as used

5 herein refers to a group -CO₂H.

The term "acyl" (or "alkanoyl") as used herein denotes a group of formula -C(=O)R wherein R is hydrogen or lower alkyl as defined herein. The term "alkylcarbonyl" as used herein denotes a group of formula C(=O)R wherein R is alkyl as defined herein. The term C₁₋₆ acyl or "alkanoyl" refers to a group -C(=O)R contain 1 to 6 carbon atoms. The C₁ acyl group is the formyl group
 10 wherein R = H and a C₆ acyl group refers to hexanoyl when the alkyl chain is unbranched. The term "arylcabonyl" or "aroyl" as used herein means a group of formula C(=O)R wherein R is an aryl group; the term "benzoyl" as used herein an "arylcabonyl" or "aroyl" group wherein R is phenyl.

The term "cyclic amine" as used herein refers to a saturated carbon ring, containing from 3 to 6 carbon
 15 atoms as defined above, and wherein at least one of the carbon atoms is replaced by a heteroatom selected from the group consisting of N, O or S for example, piperidine, piperazine, morpholine, thiomorpholine, di-oxo-thiomorpholine, pyrrolidine, pyrazoline, imidazolidine, azetidine wherein the cyclic carbon atoms are optionally substituted by one or more substituents, selected from the group consisting of halogen, hydroxy, phenyl, lower alkyl, lower alkoxy or 2-hydrogen atoms on a carbon are both replace by oxo
 20 (=O). When the cyclic amine is a piperazine, one nitrogen atom can be optionally substituted by C₁₋₆ alkyl, C₁₋₆ acyl, C₁₋₆ alkylsulfonyl.

The terms "alkylsulfonyl" and "arylsulfonyl" as used herein denotes a group of formula -S(=O)₂R wherein R is alkyl or aryl respectively and alkyl and aryl are as defined herein. The term C₁₋₃ alkylsulfonylamido as used herein refers to a group RSO₂NH- wherein R is a C₁₋₃
 25 alkyl group as defined herein. The terms C₁₋₆ haloalkylsulfonyl, C₃₋₇ cycloalkylsulfonyl, C₃₋₇ cycloalkyl-C₁₋₃ alkyl-sulfonyl or C₁₋₆ alkoxy-C₁₋₆ alkylsulfonyl refer to a compound, S(=O)₂R wherein R is C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₃ alkyl and C₁₋₆ alkoxy-C₁₋₆ alkyl, respectively


The term "sulfamoyl" as used herein refers to the radical -S(O)₂NH₂. The terms "N-
 30 alkylsulfamoyl" and "N, N-dialkylsulfamoyl" as used herein refers to the radical -S(O)₂NR'R",

wherein R' and R'' are hydrogen and lower alkyl and R' and R'' are independently lower alkyl respectively. Examples of N-alkylsulfamoyl substituents include, but are not limited to methylaminosulfonyl, iso-propylaminosulfonyl. Examples of N,N-dialkylsulfamoyl substituents include, but are not limited to dimethylaminosulfonyl, iso-propyl-methylaminosulfonyl.

- 5 The term "carbamoyl" as used herein means the radical $-\text{CONH}_2$. The prefix "N-alkylcarbamoyl" and "N,N-dialkylcarbamoyl" means a radical CONHR' or $\text{CONR}'\text{R}''$ respectively wherein the R' and R'' groups are independently alkyl as defined herein. The prefix "N-arylcarbamoyl" denotes the radical CONHR' wherein R' is an aryl radical as defined herein.

- 10 The term "pyridine" ("pyridinyl") refers to a six-membered heteroaromatic ring with one nitrogen atom. The terms "pyrimidine" ("pyrimidinyl"), "pyrazine" ("pyrazinyl") and "pyridazine" ("pyridazinyl") refer to a six-membered nonfused heteroaromatic ring with two nitrogen atoms disposed in a 1,3, a 1,4 and a 1,2 relationship respectively. The respective radical names are in parentheses.

- To avoid any ambiguity, as used herein the terms (i) 3-oxo-3,4-dihydro-pyrazin-2-yl, (ii) 3-oxo-2,3-dihydro-pyridazin-4-yl, (iii) 6-oxo-1,6-dihydro-pyrimidin-5-yl, (iv) 6-oxo-1,6-dihydro-[1,2,4]triazin-5-yl, (v) 2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl and (vi) 4,6-dioxo-1,4,5,6-tetrahydro-pyrimidin-5-yl refer to the following moieties



- 20 The phrase "substituted at least by $(\text{CH}_2)_n\text{NR}^c\text{R}^d$ " simply indicates the ring is substituted by $(\text{CH}_2)_n\text{NR}^c\text{R}^d$ but other additional optional substitutions within the scope of the claim are permitted.

- Compounds of the present invention and their isomeric forms and pharmaceutically acceptable salts thereof are also useful in treating and preventing viral infections, in particular, hepatitis C infection, and diseases in living hosts when used in combination with each other and with other biologically active agents, including but not limited to the group consisting of interferon, a pegylated interferon, ribavirin, protease inhibitors, polymerase inhibitors, small interfering RNA
- 25

compounds, antisense compounds, nucleotide analogs, nucleoside analogs, immunoglobulins, immunomodulators, hepatoprotectants, anti-inflammatory agents, antibiotics, antivirals and anti-infective compounds. Such combination therapy may also comprise providing a compound of the invention either concurrently or sequentially with other medicinal agents or potentiators, such as ribavirin and related compounds, amantadine and related compounds, various interferons such as, for example, interferon-alpha, interferon-beta, interferon gamma and the like, as well as alternate forms of interferons such as pegylated interferons. Additionally combinations of ribavirin and interferon, may be administered as an additional combination therapy with at least one of the compounds of the present invention.

- 10 In one embodiment, the compounds of the present invention according to formula I are used in combination with other active therapeutic ingredients or agents to treat patients with an HCV viral infection. According to the present invention, the active therapeutic ingredient used in combination with the compound of the present invention can be any agent having a therapeutic effect when used in combination with the compound of the present invention. For example, the active agent used in combination with the compound of the present invention can be interferons, ribavirin analogs, HCV NS3 protease inhibitors, nucleoside inhibitors of HCV polymerase, non-nucleoside inhibitors of HCV polymerase, and other drugs for treating HCV, or mixtures thereof.

Examples of the nucleoside NS5b polymerase inhibitors include, but are not limited to NM-283, valopicitabine, R1626, PSI-6130 (R1656), IDX184 and IDX102 (Idenix) BILB 1941.

- 20 Examples of the non-nucleoside NS5b polymerase inhibitors include, but are not limited to HCV-796 (ViroPharma and Wyeth), MK-0608, MK-3281 (Merck), NM-107, R7128 (R4048), VCH-759, GSK625433 and GSK625433 (Glaxo), PF-868554 (Pfizer), GS-9190 (Gilead), A-837093 and A848837 (Abbot Laboratories), ANA598 (Anadys Pharmaceuticals); GL100597 (GNLB/NVS), VBY 708 (ViroBay), benzimidazole derivatives (H. Hashimoto *et al.* WO 01/47833, H. Hashimoto *et al.* WO 03/000254, P. L. Beaulieu *et al.* WO 03/020240 A2; P. L. Beaulieu *et al.* US 6,448,281 B1; P. L. Beaulieu *et al.* WO 03/007945 A1), benzo-1,2,4-thiadiazine derivatives (D. Dhanak *et al.* WO 01/85172 A1, filed 5/10/2001; D. Chai *et al.*, WO2002098424, filed 6/7/2002, D. Dhanak *et al.* WO 03/037262 A2, filed 10/28/2002; K. J. Duffy *et al.* WO03/099801 A1, filed 5/23/2003, M. G. Darcy *et al.* WO2003059356, filed 10/28/2002; D. Chai *et al.* WO 2004052312, filed 6/24/2004, D. Chai *et al.* WO2004052313, filed 12/13/2003; D. M. Fitch *et al.*, WO2004058150, filed 12/11/2003; D. K. Hutchinson *et al.* WO2005019191, filed 8/19/2004; J. K. Pratt *et al.* WO 2004/041818 A1, filed 10/31/2003), 1,1-dioxo-4H-benzo[1,4]thiazin-3-yl derivatives (J. F. Blake

et al. in U. S. Patent Publication US20060252785 and 1,1-dioxo-benzo[d]isothazol-3-yl compounds (J. F. Blake *et al.* in U. S. Patent Publication 2006040927).

Examples of the HCV NS3 protease inhibitors include, but are not limited to SCH-503034 (Schering, SCH-7), VX-950 (telaprevir, Vertex), BILN-2065 (Boehringer-Ingelheim, BMS-605339 (Bristol Myers Squibb), and ITMN-191 (Intermune).

Examples of the interferons include, but are not limited to pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha (Infergen), feron, reaféron, intermax alpha, r-IFN-beta, Infergen and actimmune, IFN-omega with DUROS, albuferon, locteron, Albuferon, Rebif, oral interferon alpha, IFNalpha-2b XL, AVI-005, PEG-Infergen, and pegylated IFN-beta.

Ribavirin analogs and the ribavirin prodrug viramidine (taribavirin) have been administered with interferons to control HCV. Commonly used abbreviations include: acetyl (Ac), aqueous (aq.), atmospheres (Atm), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), *tert*-butoxycarbonyl (Boc), di-*tert*-butyl pyrocarbonate or boc anhydride (BOC₂O), benzyl (Bn), butyl (Bu), Chemical Abstracts Registration Number (CASRN), benzyloxycarbonyl (CBZ or Z), carbonyl diimidazole (CDI), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), N,N'-dicyclohexylcarbodiimide (DCC), 1,2-dichloroethane (DCE), dichloromethane (DCM), diethyl azodicarboxylate (DEAD), di-*iso*-propylazodicarboxylate (DIAD), di-*iso*-butylaluminumhydride (DIBAL or DIBAL-H), di-*iso*-propylethylamine (DIPEA), N,N-dimethyl acetamide (DMA), 4-N,N-dimethylaminopyridine (DMAP), N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), ethyl (Et), ethyl acetate (EtOAc), ethanol (EtOH), 2-ethoxy-2H-quinoline-1-carboxylic acid ethyl ester (EEDQ), diethyl ether (Et₂O), O-(7-azabenzotriazole-1-yl)-N, N,N'-tetramethyluronium hexafluorophosphate acetic acid (HATU), acetic acid (HOAc), 1-N-hydroxybenzotriazole (HOBt), high pressure liquid chromatography (HPLC), *iso*-propanol (IPA), methanol (MeOH), melting point (mp), MeSO₂- (mesyl or Ms), methyl (Me), acetonitrile (MeCN), m-chloroperbenzoic acid (MCPBA), mass spectrum (ms), methyl *tert*-butyl ether (MTBE), N-methylmorpholine (NMM), N-methylpyrrolidone (NMP), phenyl (Ph), propyl (Pr), *iso*-propyl (i-Pr), pounds per square inch (psi), pyridine (pyr), room temperature (rt or RT), satd. (saturated), *tert*-butyldimethylsilyl or t-BuMe₂Si (TBDMS), triethylamine (TEA or Et₃N), triflate or CF₃SO₂- (Tf), trifluoroacetic acid (TFA), O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), thin layer chromatography (TLC), tetrahydrofuran (THF), tetramethylethylenediamine (TMEDA), trimethylsilyl or Me₃Si (TMS), p-toluenesulfonic acid monohydrate (TsOH or pTsOH), 4-Me-C₆H₄SO₂-

or tosyl (Ts), N-urethane-N-carboxyanhydride (UNCA). Conventional nomenclature including the prefixes normal (*n*-), iso (*i*-), secondary (*sec*-), tertiary (*tert*-) and *neo*- have their customary meaning when used with an alkyl moiety. (J. Rigaudy and D. P. Klesney, Nomenclature in Organic Chemistry, IUPAC 1979 Pergamon Press, Oxford.).

- 5 Compounds of the present invention can be made by a variety of methods depicted in the illustrative synthetic reaction schemes shown and described below. The starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's *Reagents for*
10 *Organic Synthesis*; Wiley & Sons: New York, Volumes 1-21; R. C. LaRock, *Comprehensive Organic Transformations*, 2nd edition Wiley-VCH, New York **1999**; *Comprehensive Organic Synthesis*, B. Trost and I. Fleming (Eds.) vol. 1-9 Pergamon, Oxford, **1991**; *Comprehensive Heterocyclic Chemistry*, A. R. Katritzky and C. W. Rees (Eds) Pergamon, Oxford **1984**, vol. 1-9; *Comprehensive Heterocyclic Chemistry II*, A. R. Katritzky and C. W. Rees (Eds) Pergamon,
15 Oxford **1996**, vol. 1-11; and *Organic Reactions*, Wiley & Sons: New York, **1991**, Volumes 1-40. The following synthetic reaction schemes are merely illustrative of some methods by which the compounds of the present invention can be synthesized, and various modifications to these synthetic reaction schemes can be made and will be suggested to one skilled in the art having referred to the disclosure contained in this Application.
- 20 The starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.

- Unless specified to the contrary, the reactions described herein preferably are conducted under
25 an inert atmosphere at atmospheric pressure at a reaction temperature range of from about -78 °C to about 150 °C, more preferably from about 0° C to about 125° C, and most preferably and conveniently at about room (or ambient) temperature, e.g., about 20° C.

- In general, the nomenclature used in this Application is based on AUTONOMTM v.4.0, a Beilstein Institute computerized system for the generation of IUPAC systematic nomenclature.
30 If there is a discrepancy between a depicted structure and a name given that structure, the depicted structure is to be accorded more weight. In addition, if the stereochemistry of a

structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it

Examples of representative compounds encompassed by the present invention and within the scope of the invention are provided in the following Table. These examples and preparations
 5 which follow are provided to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.

Compounds encompassed by the present invention are substituted 3-phenyl-1H-pyridin-2-one derivatives. The following numbering scheme is used to refer to the substitution sites on the core
 10 substructure.











TABLE I

Cpd. No.	Structure	ms ¹	mp	NS5B pol inhibition ² IC ₅₀
I-1		456	238.0-240.0	0.015
I-2		420	181.0-185.0	0.71
I-3		474	130.0-132.0	0.041

Cpd. No.	Structure	ms ¹	mp	NS5B pol inhibition ² IC ₅₀
I-4		471		0.006
I-5		442		0.092
I-6		440	280.0-282.0	0.454
I-7		488		0.0003
I-8		484	>300	0.0013
I-9		496		0.0002
I-10		424	283.0-285.0	0.007

Cpd. No.	Structure	ms ¹	mp	NS5B pol inhibition ² IC ₅₀
I-11		454		0.004
I-12		243	175.0-176.0	0.390
I-13		454	240.0-242.0	0.004
I-14		361	100.0-102.0	0.007
I-15		424		0.003
I-16		259	202.0-204.0	0.132
I-17		468	292.0-294.0	0.01

Cpd. No.	Structure	ms ¹	mp	NS5B pol inhibition ² IC ₅₀
I-18		458	234.0-236.0	
I-19		393	174.0-176.0	0.015
I-20		475	250.0-252.0	0.005 0.003 ²
I-21		438	255.0-257.0	0.002 ²
I-22		454	253.0-255.0	0.002 ²
I-23		438	302.0-304.0	0.019 ²
I-24		618		0.011 ²

Cpd. No.	Structure	ms ¹	mp	NS5B pol inhibition ² IC ₅₀
I-25		470	>300	
I-26		428	269.0-271.0	0.0021
I-27		468		0.0003
I-28		484	>300	0.0006
I-29		471		0.0012
I-30		504	292.0-295.0	0.0003
I-31		488	241.0-243.0	0.0003

Cpd. No.	Structure	ms ¹	mp	NS5B pol inhibition ² IC ₅₀
I-32			>300	0.005
I-33		497	>300	0.0026
I-34		484	296.0-299.0	0.0006
I-35		480 [M-H]	255.0-258.0	0.0005
I-36		455	253.0-256.0	0.0004
I-37		478 [M-H]	478	0.0007
I-38		494 [M-H]		0.0014


Cpd. No.	Structure	ms ¹	mp	NS5B pol inhibition ² IC ₅₀
I-39		528		0.0009
I-40			172.0-175.0	0.0028
I-41		484		0.0004
I-42		496 [M-H]	202-205	0.0067
I-43				0.0011
1. mass spectra reported as (M+H) ⁺ 2. IC ₅₀ for inhibition of HCV NS5B polymerase (μM). See example 32 3. IC ₅₀ for inhibition of HCV NS5B polymerase (μM) as in Example 32 except RNA template concentration was 3 nM				

Compounds in following schemes are frequently depicted with generalized substituents to exemplify the general nature of the methodology. One skilled in the art will immediately appreciate that the nature of the R groups can be varied to afford the various compounds

5 contemplated in this invention. Moreover, the reaction conditions are exemplary and alternative conditions are well known which can be substituted for the conditions described herein. The

reaction sequences in the following examples are not meant to limit the scope of the invention as set forth in the claims.

SCHEME A



3-Aryl-1H-pyrazin-2-ones (A-4) can generally be prepared by a palladium-catalyzed Suzuki coupling of a 2-halo-3-alkoxy-pyrazine or 2-halo-3-aralkoxy-pyrazine (A-1) and pinacol-boronic acid esters [B(OR)₂ derivatives wherein both OR radicals taken together represent - OC(Me)₂CC(Me)₂O-] (A-2). The boronic esters are generally prepared by metallation of the corresponding aryl halide (A-5) and condensation with a suitable reactive boronic acid ester or dialkoxyboron halide or by Pd-catalyzed coupling with *bis*-(pincolato)diboron. Cleavage of the ether 2-alkoxy-pyrazine (HBr/HOAc) or the 2-benzyloxy-pyrazine (catalytic hydrogenolysis or HBr/HOAc) affords the 1H-pyrazin-2-one. The Suzuki coupling is a palladium-catalyzed coupling of a boronic acid with an aryl or vinyl halide or triflate. Typical catalysts include Pd(PPh₃)₄, PdCl₂(PPh₃)₂, Pd(OAc)₂ and PdCl₂(dppf). With PdCl₂(dppf), primary alkyl borane compounds can be coupled to aryl or vinyl halide or triflate without *beta*-elimination. The reaction can be carried out in a variety of organic solvents including toluene, THF, dioxane, DCE, DMF, DMSO, PhMe, MeOH and MeCN, aqueous solvents and under biphasic conditions. Reactions are typically run from about RT to about 150° C. Additives (*e.g.*, CsF, KF, TIOH, NaOEt and KOH) frequently accelerate the coupling. Although there are numerous components in the Suzuki reaction including the particular palladium catalyst, the ligand, additives, solvent, temperature, *etc.*, numerous protocols have been identified. Highly active catalysts have been described (see, *e.g.*, R. Martin and S. L. Buchwald, *Acc. Chem Res.* **2008** 41(11):1461-73, J. P.

Wolfe *et al.*, *J. Am. Chem. Soc.* **1999** 121(41):9550-9561 and A. F. Littke *et al.*, *J. Am. Chem. Soc.* **2000** 122(17):4020-4028). One skilled in the art will be able to identify a satisfactory protocol without undue experimentation.

Compounds of the present invention wherein R^b is an optionally substituted (E)-styryl- or (E)-2-heteroaryl-vinyl radical are prepared from precursors wherein R^b is an aldehyde utilizing a Wittig reaction or variant thereof. The Wittig reaction is the reaction of an aldehyde or ketone with a triphenyl phosphonium ylide to afford an alkene and triphenylphosphine oxide. (A. Maercker, *Org. React.* **1965**, 14, 270-490; A. W. Carruthers, *Some Modern Methods of Organic Synthesis*, Cambridge University Press, Cambridge, UK, **1971**, pp 81-90) Wittig reactions are most commonly used to couple aldehydes and ketones to singly substituted phosphine ylides. The Wittig reagent is usually prepared from a phosphonium salt, which is in turn made by the reaction of Ph_3P with an alkyl or aralkyl halide. To form the Wittig reagent (ylide), the phosphonium salt is suspended in a solvent such as Et_2O or THF and a strong base such as phenyl lithium or *n*-butyl lithium is added. With simple ylides, the product is usually mainly the Z-isomer, although a lesser amount of the E-isomer also is often formed. This is particularly true when ketones are used. If the reaction is performed in DMF in the presence of LiI or NaI, the product is almost exclusively the Z-isomer. If the E-isomer is the desired product, the Schlosser modification may be used. Alternatively the Horner-Wadsworth-Emmons reaction (B. E. Maryanoff and A. B. Reitz, *Chem Rev.* **1989** 89:863-927) is the chemical reaction of stabilized phosphonate carbanions with aldehydes (or ketones) to produce predominantly E-alkenes. In contrast to phosphonium ylides used in the Wittig reaction, phosphonate-stabilized carbanions are more nucleophilic and more basic. Optionally substituted (E)-2-aryl ethyl- or (E)-2-heteroaryl-ethyl derivatives are accessible by hydrogen of the olefinic linkage. Introduction of substituted aryl and heteroaryl moieties are easily accommodate by the Wittig and related olefination procedures.

Compounds of formula **I** wherein R^2 is $CONR^5Ar^1$ are prepared by oxidation of the corresponding aldehyde to the carboxylic acid. Oxidation of an alcohol is typically carried out in solvents such as DMF, NMP, DMSO, THF, dioxane, and DCM at temperatures between 0° C and 100° C. Typically used reagents are pyridinium dichromate in methylene chloride (Corey, *et al.*, *Tetrahedron Lett.* **1979** 399), DMSO/oxalyl chloride in DCM (Omura, *et al.*, *Tetrahedron* **1978** 34:1651), pyridine-sulfur trioxide complex, Dess-Martin periodinane (D. B. Dess and J. C. Martin, *J. Org. Chem.* **1983** 48:4155-4156) or 2-iodoxybenzoic acid (Robert K. Boeckman, Jr.,

et al., *Organic Synthesis Collective Volume* **2004** 10:696). Benzyl and allylic alcohols are conveniently oxidized with manganese (IV) dioxide.

Transformation of a carboxylic acid into an amide can be effected by preparing an activated carboxylic acid such as an acid chloride or a symmetrical or mixed acid anhydride and reacting
5 the activated derivative with an amines in a solvent such as DMF, DCM, THF, with or without water as a co-solvent, and the like at temperatures between 0° and 60° C generally in the presence of a base such as Na₂CO₃, NaHCO₃, K₂CO₃, DIPEA, TEA or pyridine and the like to afford an amide. Carboxylic acids are converted into their acid chlorides using standard reagents well known to one skilled in the art, such as thionyl chloride, oxalyl chloride, phosphoryl
10 chloride and the like. Those reagents can be used in presence of bases such as DIPEA, TEA or pyridine in inert solvent such as dichloromethane or dimethylformamide.

Alternatively a carboxylic acid can be converted *in situ* into activated acids by different procedures developed for peptide coupling and well-known to those skilled in the art. These activated acids were reacted directly with the amines to afford amides. Said activation can
15 involve the use of an activating agent like EDIC, DCC, HOBt, BOP, PyBrOP or 2-fluoro-1-methylpyridinium *p*-toluenesulphonate (Mukaiyama's reagent) and the like with or without a base such NMM, TEA or DIPEA in an inert solvent such as DMF or DCM at temperatures between 0° C and 60° C. The reaction may alternatively be carried out in presence of *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HATU) or 1-
20 hydroxy-7-azabenzotriazole (HOAt) and TEA or DIPEA in DMF, DCM or THF. (*Organic Synthesis*, E. Winterfeldt, ed., vol. 6, Pergamon Press, Oxford **1991** pp. 381-411; see R. C. Larock, *Comprehensive Organic Transformations – A Guide to Functional Group Preparations* **1989**, VCH Publishers Inc., New York; pp. 972-976)


Compounds of formula wherein **R²** is **NR⁵COAr¹** are prepared from the corresponding
25 nitrobenzene (**A-2**, **R^b** = NO₂). Reduction of a nitro group to an amine is typically carried out with a reducing agent in an inert solvent, e.g. MeOH, EtOH, EtOAc, THF or mixtures thereof. The reduction may be carried out by hydrogenation in the presence of a metal catalyst, e.g. nickel catalysts such as Raney nickel, palladium catalysts such as Pd/C, platinum catalysts such as PtO₂, or ruthenium catalysts such as RuCl₂(Ph₃P)₃ under H₂ atmosphere or in the presence of
30 hydrogen sources such as hydrazine or formic acid. If desired, the reaction is carried out under acidic conditions, e.g. in the presence of HCl or HOAc. The reduction may also be carried out in

the presence of a suitable hydride reducing agent such as LiAlH_4 , LiBH_4 or a metal such as Fe, Sn or Zn, in a reaction inert solvent, *e.g.* MeOH, EtOH, diglyme, benzene, toluene, xylene, *o*-dichlorobenzene, DCM, DCE, THF, dioxane, or mixtures thereof or without solvent. If desired, when the reducing reagent is Fe, Sn or Zn, the reaction is carried out under acidic conditions in the presence of water. For the preparation of stilbene derivatives, reduction of the nitro group with Sn, Fe or Zn can be used to preserve the olefinic linkage. Formation of the amide can then be carried out as described above.

Alternatively, compounds of formula **I** wherein R^2 is NR^5COAr^1 are prepared from the corresponding bromobenzene (**A-2**, $\text{R}^b = \text{Br}$) by a copper-catalyzed amidation of an aryl halide. (C. P. Jones *et al.*, *J. Org. Chem.* **2007** 72(21):7968-7973; A. Klapars *et al.*, *J. Am. Chem. Soc.* **2002** 124(25):7421-7428) The couplings can be carried out with an amide and an aryl iodide, chloride or bromide in the presence of CuI and 1,2-diamine ligands.

One skilled in the art will appreciate that the sequence of the transformations is not critical and, *e.g.*, the R^b substituent can be elaborated prior to coupling with the pyrazine fragment.

SCHEME B



4-Aryl-2H-pyridazin-3-one (**B-3b**) are prepared by condensation of an optionally substituted 4,5-dichloro-2H-pyridazin-3-one (**B-1**) and an aryl Grignard reagent to afford the 5-chloro-4-aryl-2H-pyridazin-3-one (**B-3a**) which is reductively dechlorinated to yield **B-3b** and subsequently brominated to afford **B-4**. The 2-(hetero)arylvinyl radical is introduced by a Suzuki coupling

using a 2 (hetero)aryl-vinyl boronate ester **B-5**. Alternatively, a 3-oxo-2,3-dihydro-pyridazin-4-yl boronic acid or an ester thereof (*e.g.* **108**, example 9) may be coupled with an aryl halide such as **A-5** wherein **X** is bromo or iodo.


5 5-Aryl-3H-pyrimidin-4-one derivatives can be by condensation of an arylacetonitrile, formamide and ammonia to afford a 4-amino-5-aryl-pyrimidine which can be hydrolyzed to the pyrimidine with aqueous hydrochloric acid. (W. H. Davies and H. A. Piggott, *J. Chem. Soc.* **1945** 347-351) Elaboration of the remaining substituents can then be carried out as described below.

Alternatively 2-alkoxy-pyrimidin-5-yl boronic acids or an ester thereof such as B-(4-methoxy-5-pyrimidinyl)-boronic acid (CASRN 909187-37-7) may be coupled with an aryl halide such as **A-**
10 **5** wherein **X** is bromo or iodo. Substituted pyrimidinyl boronic acids also have been described and are commercially available such as B-(2,4-dimethoxy-5-pyrimidinyl)-boronic acid (CASRN 89641-18-9), 2-chloro-4-(phenylmethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyrimidine (CASRN 1073354-22-9).

Compounds of formula **I** wherein **A** is 2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl are prepared
15 using an analogous palladium-catalyzed of an aryl halide (**A-5**, **X** is bromo or iodo) utilizing B-(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)-boronic acid (CASRN 70523-22-7). The isomeric 4,6-dioxo-1,4,5,6-tetrahydro-pyrimidin-5-yl moiety was introduced by a palladium-catalyzed coupling of dimethyl malonate to insert the C-C link to the phenyl core and subsequently completing the ring by condensing the diester with acetamidine (see, *e.g.*, example 26).

20 Compounds of formula **I** wherein **A** is 6-oxo-1,6-dihydro-[1,2,4]triazin-5-yl are prepared by introduction of an α -amino-acetic substituent which is subsequently condensed sequentially with dimethoxymethyl-dimethyl-amine and hydrazine to elaborate the 6-oxo-1,6-dihydro-[1,2,4]triazinyl ring.

SCHEME C



Compounds of the present invention with a 1-methyl-cyclopropyl substituent were prepared from 2-(1-methyl-cyclopropyl)-phenol (CASRN 4333684-77-6) as depicted in SCHEME C.

- 5 Sequential formylation and bromination-affords **C-2a** which can be O-alkylated with iodomethane in the presence of base to afford **C-2b** which can be further transformed by procedures described previously. 5-Bromo-3-(1-difluoromethyl-cyclopropyl)-2-methoxy-benzaldehyde was prepared from 5-bromo-salicylaldehyde (**162a**). The phenolic oxygen is protected and the formyl substituent is converted to a cyano methyl by reduction to the benzyl
- 10 alcohol, mesylation and displacement of the mesyl group by sodium cyanide. Dialkylation of the methylene with ethylene dibromide introduces the cyclopropyl ring. Conversion of the nitrile to a desired difluoromethyl was accomplished by reduction of the nitrile to the aldehyde and fluorination of the aldehyde with an electrophilic fluorinating agent such as DAST. Sequential formylation and O-alkylation with iodomethane in the presence of base affords **170**. In these
- 15 two examples the stilbene is introduced utilizing a Horner-Wadsworth-Emmons reaction followed by palladium catalyzed coupling to introduce the heteroaryl substituent. 5,7-Diiodo-4-

methoxy-3,3-dimethyl-2,3-dihydro-benzofuran is prepared by O-alkylation of 2,6-dibromo-phenol with 3-bromo-2-methyl-propene to afford **148** and subjecting resulting ether to a free-radical cyclization to afford 4-hydroxy-3,3-dimethyl-2,3-dihydro-benzofuran (**150**). Sequential dihalogenation and O-alkylation of the phenol affords **152b**. Sequential palladium-catalyzed coupling **108** and **156** affords compounds of the present invention. 5,7-Dibromo-3,3-dimethyl-2,3-dihydro-benzofuran is prepared analogously except 2,6-dibromo-phenol is replaced by 2-bromo-phenol to afford 3,3-dimethyl-2,3-dihydro-benzofuran which subsequently is dihalogenated to produce **102**.

The activity of the inventive compounds as inhibitors of HCV activity may be measured by any of the suitable methods known to those skilled in the art, including in vivo and in vitro assays. For example, the HCV NS5B inhibitory activity of the compounds of formula I can be determined using standard assay procedures described in Behrens *et al.*, *EMBO J.* **1996** 15:12-22, Lohmann *et al.*, *Virology* **1998** 249:108-118 and Ranjith-Kumar *et al.*, *J. Virology* **2001** 75:8615-8623.

Unless otherwise noted, the compounds of this invention have demonstrated in vitro HCV NS5B inhibitory activity in such standard assays. The HCV polymerase assay conditions used for compounds of the present invention are described in Example 8. Cell-based replicon systems for HCV have been developed, in which the nonstructural proteins stably replicate subgenomic viral RNA in Huh7 cells (V. Lohmann *et al.*, *Science* **1999** 285:110 and K. J. Blight *et al.*, *Science* **2000** 290:1972). The cell-based replicon assay conditions used for compounds of the present invention are described in Example 4. In the absence of a purified, functional HCV replicase consisting of viral non-structural and host proteins, our understanding of Flaviviridae RNA synthesis comes from studies using active recombinant RNA-dependent RNA-polymerases and validation of these studies in the HCV replicon system. Inhibition of recombinant purified HCV polymerase with compounds *in vitro* biochemical assays may be validated using the replicon system whereby the polymerase exists within a replicase complex, associated with other viral and cellular polypeptides in appropriate stoichiometry. Demonstration of cell-based inhibition of HCV replication may be more predictive of in vivo function than demonstration of HCV NS5B inhibitory activity *in vitro* biochemical assays.

The compounds of the present invention may be formulated in a wide variety of oral administration dosage forms and carriers. Oral administration can be in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions, syrups, or suspensions. Compounds of the present invention are efficacious when administered by other routes of administration including continuous (intravenous drip) topical parenteral,

intramuscular, intravenous, subcutaneous, transdermal (which may include a penetration enhancement agent), buccal, nasal, inhalation and suppository administration, among other routes of administration. The preferred manner of administration is generally oral using a convenient daily dosing regimen which can be adjusted according to the degree of affliction and the patient's response to the active ingredient.

A compound or compounds of the present invention, as well as their pharmaceutically useable salts, together with one or more conventional excipients, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use. A typical preparation will contain from about 5% to about 95% active compound or compounds (w/w). The term "preparation" or "dosage form" is intended to include both solid and liquid formulations of the active compound and one skilled in the art will appreciate that an active ingredient can exist in different preparations depending on the target organ or tissue and on the desired dose and pharmacokinetic parameters.

The term "excipient" as used herein refers to a compound that is useful in preparing a pharmaceutical composition, generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. The compounds of this invention can be administered alone but will generally be administered in admixture with one or more suitable pharmaceutical excipients, diluents or carriers selected with regard to the intended route of administration and standard pharmaceutical practice.

"Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for human pharmaceutical use.

A "pharmaceutically acceptable salt" form of an active ingredient may also initially confer a desirable pharmacokinetic property on the active ingredient which were absent in the non-salt form, and may even positively affect the pharmacodynamics of the active ingredient with respect to its therapeutic activity in the body. The phrase "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.

Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. Solid form preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

Liquid formulations also are suitable for oral administration include liquid formulation including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions. These include solid form preparations which are intended to be converted to liquid form preparations shortly before use. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or
5 may contain emulsifying agents such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known
10 suspending agents.

The compounds of the present invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or
15 emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in
20 powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.

The compounds of the present invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable
25 thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert
30 base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

The compounds of the present invention may be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to
5 solidify.

The compounds of the present invention may be formulated for vaginal administration.

Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate. The compounds of the present invention may be formulated for nasal administration. The solutions or suspensions are applied
10 directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray. The formulations may be provided in a single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.

15 The compounds of the present invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration. The compound will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. The active ingredient is provided in a pressurized pack with a suitable propellant such as a
20 chlorofluorocarbon (CFC), for example, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by a metered valve. Alternatively the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch
25 derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). The powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of *e.g.*, gelatin or blister packs from which the powder may be administered by means of an inhaler.

When desired, formulations can be prepared with enteric coatings adapted for sustained or
30 controlled release administration of the active ingredient. For example, the compounds of the present invention can be formulated in transdermal or subcutaneous drug delivery devices.

These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with a treatment regimen is crucial. Compounds in transdermal delivery systems are frequently attached to an skin-adhesive solid support. The compound of interest can also be combined with a penetration enhancer, *e.g.*, Azone (1-dodecylazacycloheptan-2-one). Sustained release delivery systems are inserted subcutaneously into to the subdermal layer by surgery or injection. The subdermal implants encapsulate the compound in a lipid soluble membrane, *e.g.*, silicone rubber, or a biodegradable polymer, *e.g.*, polylactic acid.

Suitable formulations along with pharmaceutical carriers, diluents and excipients are described in *Remington: The Science and Practice of Pharmacy* **1995**, edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pennsylvania. A skilled formulation scientist may modify the formulations within the teachings of the specification to provide numerous formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity.

The modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (salt formulation, esterification, *etc.*), which are well within the ordinary skill in the art. It is also well within the ordinary skill of the art to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect in patients.

The term "therapeutically effective amount" as used herein means an amount required to reduce symptoms of the disease in an individual. The dose will be adjusted to the individual requirements in each particular case. That dosage can vary within wide limits depending upon numerous factors such as the severity of the disease to be treated, the age and general health condition of the patient, other medicaments with which the patient is being treated, the route and form of administration and the preferences and experience of the medical practitioner involved. For oral administration, a daily dosage of between about 0.01 and about 1000 mg/kg body weight per day should be appropriate in monotherapy and/or in combination therapy. A preferred daily dosage is between about 0.1 and about 500 mg/kg body weight, more preferred 0.1 and about 100 mg/kg body weight and most preferred 1.0 and about 10 mg/kg body weight per day. Thus, for administration to a 70 kg person, the dosage range would be about 7 mg to 0.7 g per day. The daily dosage can be administered as a single dosage or in divided dosages, typically

between 1 and 5 dosages per day. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect for the individual patient is reached. One of ordinary skill in treating diseases described herein will be able, without undue experimentation and in reliance on personal knowledge, experience and the disclosures of this application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease and patient.

In embodiments of the invention, the active compound or a salt can be administered in combination with another antiviral agent such as ribavirin, a nucleoside HCV polymerase inhibitor, another HCV non-nucleoside polymerase inhibitor or HCV protease inhibitor. When the active compound or its derivative or salt are administered in combination with another antiviral agent the activity may be increased over the parent compound. When the treatment is combination therapy, such administration may be concurrent or sequential with respect to that of the nucleoside derivatives. "Concurrent administration" as used herein thus includes administration of the agents at the same time or at different times. Administration of two or more agents at the same time can be achieved by a single formulation containing two or more active ingredients or by substantially simultaneous administration of two or more dosage forms with a single active agent.

It will be understood that references herein to treatment extend to prophylaxis as well as to the treatment of existing conditions. Furthermore, the term "treatment" of a HCV infection, as used herein, also includes treatment or prophylaxis of a disease or a condition associated with or mediated by HCV infection, or the clinical symptoms thereof.

The term "therapeutically effective amount" as used herein means an amount required to reduce symptoms of the disease in an individual. The dose will be adjusted to the individual requirements in each particular case. That dosage can vary within wide limits depending upon numerous factors such as the severity of the disease to be treated, the age and general health condition of the patient, other medicaments with which the patient is being treated, the route and form of administration and the preferences and experience of the medical practitioner involved. For oral administration, a daily dosage of between about 0.01 and about 1000 mg/kg body weight per day should be appropriate in monotherapy and/or in combination therapy. A preferred daily dosage is between about 0.1 and about 500 mg/kg body weight, more preferred 0.1 and

about 100 mg/kg body weight and most preferred 1.0 and about 10 mg/kg body weight per day. Thus, for administration to a 70 kg person, the dosage range would be about 7 mg to 0.7 g per day. The daily dosage can be administered as a single dosage or in divided dosages, typically between 1 and 5 dosages per day. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect for the individual patient is reached. One of ordinary skill in treating diseases described herein will be able, without undue experimentation and in reliance on personal knowledge, experience and the disclosures of this application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease and patient.


A therapeutically effective amount of a compound of the present invention, and optionally one or more additional antiviral agents, is an amount effective to reduce the viral load or achieve a sustained viral response to therapy. Useful indicators for a sustained response, in addition to the viral load include, but are not limited to liver fibrosis, elevation in serum transaminase levels and necroinflammatory activity in the liver. One common example, which is intended to be exemplary and not limiting, of a marker is serum alanine transaminase (ALT) which is measured by standard clinical assays. In some embodiments of the invention an effective treatment regimen is one which reduces ALT levels to less than about 45 IU/mL serum.

The modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (salt formulation, esterification, *etc.*), which are well within the ordinary skill in the art. It is also well within the ordinary skill of the art to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect in patients.

The following examples illustrate the preparation and biological evaluation of compounds within the scope of the invention. These examples and preparations which follow are provided to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.

Example 1

N-(4-{(E)-2-[5-tert-Butyl-2-hydroxy-3-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide (**I-6**) and N-(4-{2-[5-tert-butyl-2-hydroxy-3-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-ethyl}-phenyl)-methanesulfonamide (**I-5**)



step 1 – To a solution of 15-crown-5 (1.72 g) in THF (20 mL) cooled to 0 °C was added NaH (1.56 g, 3.9 mmol, 60% mineral oil dispersion) and a solution of diethyl (4-nitro-benzyl)-phosphonate (10.65 g, 3.9 mmol) and THF (20 mL). After stirring for 10 min at 0° C, a solution of **20** (5.0 g) and THF (30 mL) was added slowly. After an additional 10 min the reaction was warmed to RT then heated at reflux for 6 h. The reaction was cooled to RT, quenched with 1 N HCl and extracted with EtOAc. The combined extracts were dried, filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with 5% EtOAc to afford 9.5 g of **22a**.

step 2 - To a solution of **22a** (0.070 g, 0.19 mmol) in EtOAc (40 mL) was added SnCl₂·2H₂O (210 mg). The reaction was heated at reflux for 2 h then cooled and slowly poured into ice-cold aq. NaHCO₃. The resulting mixture was extracted with EtOAc and the combined extracts were dried, filtered and evaporated. The crude product was purified by SiO₂ chromatography eluting with 15% EtOAc to afford **22b**.

step 3 - To a solution of **22b** (0.042 g, 0.12 mmol) and pyridine (20 mL) cooled to 0° C was added methanesulfonyl chloride (9.4 µL, 0.12 mmol). After stirring for 40 min at 0 °C, the reaction mixture was diluted with EtOAc and the resulting solution was poured into 1 N HCl. The combined organic extracts were dried, filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with 25% EtOAc/hexane to afford **22c**.

step 4 - A mixture of **22c** (0.100 g, 0.24 mmol), *bis*-(pinacolato)diboron (0.0901 g, 0.35 mmol), PdCl₂(PPh₃)₂ (0.0135 g) and KOAc (0.070 g) under an Ar atmosphere was dissolved in dioxane (3.0 mL). The reaction mixture was then heated to 110 °C for 3 h, cooled to RT and partitioned between EtOAc and aq. NH₄Cl. The aqueous phase was extracted with EtOAc and the combined extracts were dried, filtered and evaporated. The crude product was purified by SiO₂ chromatography eluting with 25% EtOAc/hexane to afford **24**.

step 5 - A tube was charged with **24** (0.055 g, 0.12 mmol), 2-benzyloxy-3-chloro-pyrazine (0.0386 g, 0.017 mmol), Pd(PPh₃)₄ (0.0202 g, 0.017 mmol), Na₂CO₃ (0.038 g, 0.36 mmol), MeOH (0.3 mL) and DCM (0.9 mL). The tube and solution were sparged with Ar, sealed and heated at 115 °C for 35 min. The solution was cooled, filtered through CELITE, and the filtrate concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with 20% EtOAc/hexane to afford **26**.


step 6 - To a solution of **26** (0.034 g, 0.064 mmol) in EtOAc (2 ml)/MeOH (1 mL) was added Pd(OH)₂ (0.0135 g) and the resulting mixture stirred overnight under a hydrogen atmosphere (balloon). The reaction mixture was filtered and concentrated. The crude product was purified on a preparative SiO₂ TLC plate developed with 50% EtOAc/hexane to afford **I-5**.

step 7 - To a solution of **26** (0.075 g, 0.14 mmol) and HOAc (2.0 mL) at RT was added HBr (47.5 µL). The reaction was sealed and heated to 60 °C for 45 min. The solution was cooled to RT, diluted with EtOAc and poured into satd. NaHCO₃. The aqueous layer was extracted with EtOAc and the combined extracts dried, filtered and evaporated. The crude product was purified by SiO₂ chromatography eluting with 5% MeOH/DCM to afford **I-6**.

Example 2

N-(4-{2-[3-tert-Butyl-2-methoxy-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-ethyl}-phenyl)-methanesulfonamide (I-1) and N-(4-{2-[3-tert-Butyl-2-methoxy-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-ethyl}-phenyl)-acetamide (I-2)

-48-



5-bromo-3-*tert*-butyl-2-methoxybenzaldehyde (**28**)

To a solution of 3-*tert*-butyl-2-hydroxybenzaldehyde (CASRN 24623-65-2, 5.00 g) DCM (20 mL) at 0° C was added dropwise a solution of Br₂ (1.45 mL) in DCM (15 mL) over a period of 30 min. After the addition was complete the reaction was stirred for 1 h before the organic volatiles were removed under reduced pressure to afford 7.23 g of 5-bromo-3-*tert*-butyl-2-hydroxybenzaldehyde (**27**) as a light yellowish solid.

A mixture of **27** (3.83 g), MeI (2.32 mL) and K₂CO₃ (6.18 g) in DMF (50 mL) was heated at 50 °C for 1 h then cooled to RT and diluted with ether and water. The organic layer was thrice washed with water then brine, dried (MgSO₄) and concentrated to afford 3.99 g of 5-bromo-3-*tert*-butyl-2-methoxybenzaldehyde (**28**) as a yellow solid.

step 1 - A mixture **28** (0.60 g CASRN 417715-878), *bis*-(pinacolato)diboron (**31**, 0.69 g), Pd(dppf)₂Cl₂ (54 mg) and KOAc (542 mg) in DME (30 mL) under an argon atmosphere was heated at 70° C for 14 h and then at 90° C for additional 7 h. The reaction was cooled to RT, and diluted with water and ether. The organic layer was washed with brine, dried (MgSO₄), filtered and concentrated. The crude residue was purified by SiO₂ chromatography eluting with a EtOAc/hexane gradient (0 to 12% EtOAc) to afford 478 mg of **29** contaminated with a small amount of **31**.

step 2 – A vial was charged with **29** (0.365 g 1.48 mmol), 2-chloro-3-methoxy-pyrazine (0.198 g, 1.370 mmol), Pd(Ph₃)₄ (0.106 g, 0.092 mmol) Na₂CO₃ (0.313 g, 2.953 mmol), MeOH (6 mL) and DCM (2 mL), sealed and irradiated in a microwave synthesizer at 115 °C for 30 min. The reaction mixture was cooled to RT, diluted with EtOAc, washed with brine, dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with a EtOAc/hexane gradient (2 to 10% EtOAc) to afford 0.275 g of **30**.

step 3 – To a solution of 4-nitro-benzylphosphonium bromide (1.23 g, 2.573 mmol) and DMF (10 mL) cooled to 0 °C was added NaH (0.211 g, 5.275 mmol, 60% mineral oil dispersion). The solution was stirred for 30 min then a solution of **29** (0.251 g, 0.857 mmol) and DMF (5 mL) was added and the resulting solution stirred overnight at RT. The reaction was quenched by addition of 1N HCl (8 mL) and the resulting solution diluted with EtOAc. The EtOAc solution was separated and twice washed with brine, dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with a EtOAc/hexane gradient (5 to 10% EtOAc) to afford 317 mg of **32**.

step 4 – A stream of hydrogen was bubbled through a mixture of **32** (0.317 g, 0.757 mmol), Pd(OH)₂ (0.109 g), EtOAc (15 mL) and MeOH (15 mL). After 30 min no starting material remained and the resulting solution was filtered to remove the catalyst and evaporated. The crude product was purified by SiO₂ chromatography eluting with a EtOAc/hexane gradient (15 to 30% EtOAc) to afford 0.210 g (71%) of **34a**.

step 5 – To a solution of **34a** (0.0786 g, 0.201 mmol) in dry pyridine cooled to 0 °C was added mesyl chloride (20 µL, 0.257 mmol) and the resulting solution stirred at RT overnight. The solution was diluted with EtOAc, sequentially washed with aqueous CuSO₄, 1N HCl, dried (Na₂SO₄), filtered and evaporated to afford 0.102 g of crude product. The crude product was purified by SiO₂ chromatography eluting with a EtOAc/hexane gradient (5 to 30% EtOAc) to afford 0.081 g of **34b**.


step 7 – A vial was charged with **34b** (0.081 g, 0.173 mmol), HBr (35 µL) and HOAc (4 mL), sealed and irradiated in a microwave synthesizer at 60 °C. The solution was cooled to RT and poured into ice and aqueous NaHCO₃. The resulting mixture was extracted with EtOAc, dried (Na₂SO₄), filtered and evaporated. Residual HOAc was removed by azeotropic distillation with benzene to afford 0.0595 g of **I-1**.

step 6 – To a solution of **34a** (0.0768 g, 0.196 mmol) in dry pyridine cooled to 0 °C was added acetic anhydride (25 µL, 0.264 mmol) and the resulting solution stirred overnight at RT. The resulting solution was diluted with EtOAc and sequentially washed with aqueous CuSO₄ and 1N HCl, dried (Na₂SO₄), filtered and evaporated. The crude product was purified by SiO₂ chromatography eluting with a EtOAc/hexane gradient (25 to 50% EtOAc) to afford 0.074 g of **34c**.

step 8 – A tube was charged with **34c** (0.074 g), HBr (75 µL) and HOAc (4 mL), sealed and heated at 60 °C overnight. The solution was cooled and poured into ice and aqueous NaHCO₃, extracted with EtOAc, dried (Na₂SO₄), filtered and concentrated *in vacuo*. The resulting solid was dried by azeotropic distillation with benzene then dried *in vacuo* to afford 0.040 g of **I-2**.

Example 3

N-[3-*tert*-Butyl-2-methoxy-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-4-methanesulfonylamino-benzamide (**I-4**)



Ar = 4-methanesulfonylamido-phenyl

step 1 – To a solution of **36** (0.41 g, 0.423 mmol, CASRN 474554-50-2) in MeOH (4 mL) and H₂O (4 mL) was added sequentially NH₄Cl (0.76 g, 14.23 mmol) and Fe (0.38 g, 6.83 mmol;) and the resulting mixture heated at reflux for 1 h. The solution was cooled and filtered through a CELITE pad which was washed with MeOH. The filtrate was concentrated in vacuo and the resulting mixture extracted with EtOAc. The extract was washed with brine, dried (Na₂SO₄),

filtered and concentrated in vacuo. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 20% EtOAc) to afford 0.235 g (64%) of **38**.

Acylation of **38** (step 2) with 4-nitro-benzoic acid is carried out with EDCI, HOBt DIPEA in DMF. Reduction of the nitro group (step 3) to afford **40a** is carried out with Fe in accord with the procedure in step 1 of the current example. Sulfonylation (step 4) of **40b** is carried out as described in step 3 of example 1.


step 5 – A flask was charged with **40c** (0.15 g, 0.329 mmol), *bis*-(pinacolato)diboron (0.091 g, 0.36 mmol), KOAc (0.096 g, 0.988 mmol), PdCl₂(PPh₃)₄ (0.015 g) and dioxane (6 mL) and the resulting mixture heated at reflux for 2 h. The solution was cooled to RT and partitioned between H₂O and EtOAc. The organic extract was washed with brine, dried (Na₂SO₄), filtered and evaporated. The crude boronate ester was purified by SiO₂ chromatography eluting with EtOAc/hexane to afford 0.16 g of **42**.

step 6 – A flask was charged with **42** (0.167 g, 0.332 mmol), 2-chloro-3-methoxy-pyrazine (0.043 g, 0.329 mmol), Na₂CO₃ (0.32 g, 0.997 mmol), Pd(Ph₃)₄ (0.038 g) and DCM/MeOH (3:1) and the resulting solution heated to 110 °C for 30 min. The solution was cooled to RT, filtered and the crude product purified by SiO₂ chromatography to afford **42**.

step 7 – To a solution **42** (0.090 g) and HOAc (2 mL) was added HBr (63 µL) and the resulting solution was heated to 60 °C overnight. The temperature was elevated to 90 °C for another 24 h, cooled and the resulting solid collected by filtration. The crude product was purified by SiO₂ chromatography to afford 0.010 g of **I-4**.

Example 4

N-(4-{2-[3-tert-Butyl-4-fluoro-2-methoxy-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-ethyl}-phenyl)-methanesulfonamide



- 5 step 1 – To a solution of **46a** (4.0 g, 21 mmol), and benzyl bromide (3.50 mL, 29 mmol) and acetone (100 mL) was added K_2CO_3 (7.236 g, 52 mmol) and the resulting reaction mixture stirred at reflux overnight. The reaction was cooled to RT and the acetone evaporated. The residue was partitioned between EtOAc (200 mL) and H_2O (50 mL). The aqueous layer was extracted with EtOAc and the combined organic extracts were washed sequentially with H_2O (50
- 10 mL) and brine (50 mL). The EtOAc solution was dried (Na_2SO_4), filtered and evaporated. The

residue was purified by SiO₂ chromatography eluting with a EtOAc/hexane gradient (0 to 10% EtOAc) to afford 5.76 (98%) of **46b**.

step 2 – A round-bottom flask was charged with **46b** (53.865 g, 20 mmol) and dry THF (24 mL). The solution was cooled to –78 °C and a solution of *n*-butyl lithium/hexane (9.50 mL, 24 mmol, 2.5 M solution in hexanes) was added dropwise and the resulting solution stirred at –78 °C for 1 h. Acetone (1.9 mL, 26 mmol) was added dropwise and the resulting mixture stirred at –78 °C for an additional 15 min. The cooling bath was removed and the reaction stirred at RT for 1 h. The reaction mixture was cooled to 0 °C and quenched by addition of H₂O (30 mL) and the resulting solution extracted with EtOAc (150 mL). The aqueous phase was again extracted with EtOAc (150 mL) and the combined extracts washed sequentially with H₂O and brine. The organic phase was dried (Na₂SO₄), filtered and evaporated. The residue was purified by SiO₂ chromatography eluting with a EtOAc/hexane gradient (0 to 15% EtOAc) to afford 3.70 (72%) of **48**.

step 3 – To a solution of **48** (3.710 g, 14 mmol) and DCM (3.0 mL) was cooled to –78 °C and Ti(IV)Cl₄ (3.13 mL, 29 mmol) was added dropwise. The reaction was stirred at –78 °C for 1.5 h, then a solution of Me₂Zn and hexane (57 mL, 57 mmol, 1.0M in heptane) was added. After the addition was complete the reaction was warmed to RT and stirred for 3.5 h. The reaction mixture was poured into a mixture of ice and H₂O and the resulting mixture stirred for 30 min. The aqueous phase was extracted with DCM and the resulting extract washed with brine. The aqueous phase was twice extracted with DCM. The combined organic solutions were dried (Na₂SO₄), filtered and evaporated. The resulting product was purified by SiO₂ chromatography eluting with a EtOAc/hexane gradient (0 to 30% EtOAc) which afforded 0.5670 g of **50** and 6-benzyl-2-*tert*-butyl-3-fluorophenol.

step 4 – To a solution of **50** (0.400 g, 2 mmol) and MeCN (5 mL) was added paraformaldehyde (0.409 g (14 mmol), MgCl₂ (0.289 g, 3 mmol) and TEA (1.05 mL, 8 mmol) and the resulting suspension was stirred at reflux overnight. The reaction mixture was cooled to RT and partitioned between DCM (100 mL) and 1M HCl (20 mL). The aqueous phase was extracted with DCM and the combined DCM solutions were dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with a EtOAc/hexane gradient (0 to 5 % EtOAc) to afford 0.274 g (62%) of **52a**.

step 5 – To a solution of **52a** (0.270 g, 1 mmol) DCM (7.5 mL) and MeOH (5 mL) was added tetrabutylammonium tribromide (0.627 g, 1.05 mmol) and the resulting solution stirred at RT for 3.5 h. The reaction mixture was concentrated and the residue partitioned between EtOAc (100 mL) and H₂O (20 mL). The aqueous layer was extracted with EtOAc (100 mL) and each organic
5 extract was sequentially washed with H₂O (20 mL) and brine (20 mL). The organic extracts were combined, dried (Na₂SO₄), filtered and evaporated. The residue was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 5% EtOAc) to afford 0.120 g (35%) of **52b**.

step 6 – To a solution of **52b** (0.117 g) in DMF (2 mL) was added K₂CO₃ (0.147 g) and methyl
10 iodide (40 µL) and the resulting suspension stirred at 60 °C for 2 h. The reaction was cooled to RT and quenched with H₂O. The resulting solution was partitioned between Et₂O (50 mL) and H₂O (10 mL). The aqueous layer was extracted with Et₂O. The organic solutions were washed sequentially with H₂O (2 x 5 mL) and brine, combined, dried (Na₂SO₄), filtered and evaporated to afford 0.117 g of **54** which was sufficiently pure to use directly in the next step.

step 7 – To a mixture of NaH (0.024 g, 60% mineral oil dispersion) and THF (1.0 mL) cooled to
15 0 °C was added 15-crown-5 (0.006 g) and the resulting solution stirred for 5 min. To this mixture was added dropwise a solution of diethyl (4-nitrobenzyl)phosphonate (0.121 g, 1.1 equivalent) and THF (1.0 mL). The resulting reaction mixture was stirred for 5 min after the addition was complete then a solution of **54** (0.116 g, 1.0 equivalent) and THF (3.0 mL) was
20 added dropwise over 10 min while the reaction temperature was maintained at 0 °C. The reaction was stirred at 0 °C for 15 min followed by 1.5 h at RT. The reaction was quenched by careful addition of water. The resulting solution was partitioned between EtOAc (50 mL) and H₂O (10 mL) and the aqueous layer was withdrawn and extracted with EtOAc (50 mL). The two organic solutions were separately washed sequentially with water and brine, combined, dried
25 (Na₂SO₄), filtered and evaporated. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 10% EtOAc) to afford 0.155 g (94%) of **56**.

step 8 – A flask was charged with **56** (0.100 g), *bis*(pinacolato)diboron (0.068 g), PdCl₂(PPh₃)₂
(0.010 g), KOAc (0.072 g) and dioxane (3.0 mL) and stirred at 90 °C overnight. The reaction
30 was cooled to RT and partitioned between EtOAc (50 mL) and H₂O (10 mL) and the organic phase sequentially washed with H₂O and brine. The aqueous layer was re-extracted with EtOAc (50 mL) and the extracts were sequentially washed with H₂O and brine. The combined organic


extracts were dried (Na_2SO_4), filtered and concentrated *in vacuo*. The crude product was purified by SiO_2 chromatography eluting with an EtOAc/hexane gradient (0 to 70% EtOAc) to afford 0.042 g (32%) of **58**.

- 5 step 9 – A microwave tube was charged with **58** (0.042 g), 2-chloro-3-methoxy-pyrazine (0.015 g), $\text{Pd}(\text{PPh}_3)_4$ (0.009 g), Na_2CO_3 (0.025 g), MeOH (1.2 mL) and DCM (0.4 mL), sealed and irradiated in a microwave synthesizer at 115 °C for 30 min. The reaction was cooled and concentrated. The residue was partitioned between EtOAc (30 mL) and H_2O . The aqueous layer was withdrawn and re-extracted with EtOAc (30 mL). The extracts were sequentially washed with H_2O and brine. The combined organic extracts were dried (Na_2SO_4), filtered and
- 10 concentrated *in vacuo*. The crude product was purified by SiO_2 chromatography eluting with an EtOAc/hexane gradient (0 to 20% EtOAc) to afford 0.02 g (52%) of **60**.

Conversion of **60** to **I-3** is carried out in accord with the procedures described in steps 4, 5 and 7 of example 2.

Example 5

- 15 N-(4-{(E)-2-[3-*tert*-Butyl-2-methoxy-5-(3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide (**I-13**)



- step 1 – A dry round-bottom flask was charged with 4-bromo-2-*tert*-butylanisole (2.933 g, 0.005 mmol, CASRN 14804-34-3), THF (15 mL) and magnesium turnings (0.2 g) were added. The
- 20 reaction mixture was heated to reflux and stirred for 45 min then cooled to RT. The resulting

solution was added dropwise at RT to a stirred solution of 4,5-dichloro-3-hydroxy-pyridazine (0.796 g, CASRN 932-22-9), THF (10 mL) and Et₂O (20 mL). The reaction mixture was then heated at reflux overnight. The reaction was cooled to 0 °C and quenched with sat'd NH₄Cl and extracted with EtOAc (150 mL). The aqueous phase was withdrawn and re-extracted with EtOAc (150 mL). Each extract was washed sequentially with water and brine. The combined organic extracts were dried (Na₂SO₄), filtered and concentrated *in vacuo*. The residue was triturated with EtOAc/hexane (1:1) to afford 1.0870 g (77%) of **66a**.

step 2 – A Parr Shaker bottle was charged with **66a** (1.080 g), a solution of KOH (0.517 g) and H₂O (11 mL) and DMF (1.3 mL). To this mixture was added 10% Pd/C and the bottle was connected to a Parr shaker and flushed three times with hydrogen then shaken overnight at RT under an atmosphere of *ca* 50 psi of hydrogen. To the resulting solution was added 5M KOH to dissolve the precipitate then the solution was filtered through a glass microfiber filter and rinsed with 5M KOH and H₂O. The filtrate was acidified with con HCl and the resulting mixture extracted with DCM (100 mL). The aqueous layer was withdrawn and re-extracted with EtOAc. The combined extracts were dried (Na₂SO₄), filtered and evaporated to afford 0.791 g (83%) of **66b**.

step 3 – To a solution of **66b** (0.100 g) and DMF (2 mL) was added NBS (0.069 g) and the resulting solution stirred at 50 °C overnight. The reaction was concentrated *in vacuo* and the residue partitioned between Et₂O and H₂O. The aqueous layer was withdrawn and re-extracted with Et₂O. The organic layers were twice washed with H₂O (5 mL) and once with brine (5 mL). The organic layers were combined, dried (Na₂SO₄), filtered and evaporated. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 30% EtOAc) to afford 0.068 g (52%) yield of **68**.

step 4 – To a solution of Pd(OAc)₂ (0.076 g) and *tris*-(*ortho*-tolyl)-phosphine (0.246 g, 1 mmol) and toluene (16 mL) were added sequentially N-(4-iodo-phenyl)-methanesulfonamide (2.00 g, 7 mmol, CASRN 102294-59-7), tributyl amine (1.92 mL) and 4,4,6-trimethyl-2-vinyl-[1,3,2]dioxaborinane (1.244 g, 8 mmol, **70**) and the reaction was heated at reflux for 72 h. The reaction was cooled to RT and partitioned between Et₂O (100 mL) and 1M HCl (20 mL). The aqueous layer was withdrawn and re-extracted with Et₂O. The organic phases were washed sequentially with H₂O and brine. The extracts were combined, dried (Na₂SO₄), filtered and

evaporated. The residue was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 30% EtOAc) to afford 1.4 g (58%) of **72**.

step 5 – A microwave tube was charged with **68** (0.068 g), **72** (0.078 g), Na₂CO₃ (0.064 g), Pd(PPh₃)₄ (0.023 g), MeOH (1.8 mL) and DCM (0.6 mL). The tube was flushed with argon,

sealed and irradiated in a microwave synthesizer at 125 °C for 40 min. The reaction mixture was cooled and concentrated *in vacuo*. The residue was partitioned between DCM (25 mL) and H₂O (5 mL). The organic layer was washed with brine (5 mL). The aqueous phase was twice extracted with DCM (25 mL). The organic layers were combined, dried (Na₂SO₄), filtered and evaporated. The crude product was purified by SiO₂ chromatography eluting with a EtOAc/hexane gradient (0 to 60% EtOAc) to afford 0.175 g (18%) of **I-13**.

1-12 can be prepared in accord with the procedures in step 1 and 2 by coupling of 4,5-dichloro-3-hydroxy-pyridazine and 3-bromo-5-*tert*-butyl-toluene. **1-16** can be prepared in accord with the procedures in step 1 and 2 by coupling of 4,5-dichloro-3-hydroxy-pyridazine and 4-bromo-2-*tert*-butyl-anisole.

15 **Example 6**


N-(4-{(E)-2-[5-(2,4-Dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-3-trifluoromethyl-phenyl]-vinyl}-phenyl)-methanesulfonamide (I-35)

The title compound was prepared in accord with the sequence described in Example 31 except the starting material was 2-trifluoromethyl-phenol (CASRN 444-30-4). Bromination of 2-hydroxy-3-trifluoromethyl-benzaldehyde (244) was accomplished by stirring 244 with NBS in MeCN at RT. Reduction of the nitro group and sulfonylation of the amine to afford N-{4-[(E)-2-(5-bromo-2-methoxy-3-trifluoromethyl-phenyl)-vinyl]-phenyl}-methanesulfonamide (246) which was subjected to palladium-catalyzed coupling of with 137 to afford I-35.

Example 7

25 N-(4-{(E)-2-[3-tert-Butyl-2-methoxy-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide (I-11)

-58-



The conversion of aldehyde **28** to the stilbene **84a** can be carried out by Wadsworth-Horner-Emmons condensation with diethyl (4-nitrobenzyl)-phosphonate as described in step 1 of example 1


- 5 step 2 – A mixture of **84a** (788.3 g, 2.02 mmol), iron (471.2 mg, 8.43 mmol) and NH₄Cl (866.7 mg, 16.2 mmol) in MeOH (35 mL) and H₂O (30 mL) was heated at reflux for 4 h. The reaction mixture was cooled to RT and filtered. The filtrate was thrice extracted with EtOAc and the combined extracts washed with brine, dried (Na₂SO₄), filtered and concentrated *in vacuo* to afford 709 mg (95%) of **84b** as a yellow solid.
- 10 The remaining steps sulfonylation of the amine (step 3), introduction of the pinacolborane (step 4), Suzuki coupling with 2-chloro-3-methoxy-pyrazine (step 5) and cleavage of the pyrazine ether (step 6) can be carried out according to the procedures in step 3, 4, and 5 of example 1 and step 8 of example 2 respectively.

- I-10** can be prepared analogously except in step 1, **28** is replaced with 3-bromo-5-*tert*-butyl-benzaldehyde [CASRN 241155-25-1].
- 15

Example 8

N-(4-{(E)-2-[3-*tert*-Butyl-5-(5-chloro-3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide (**I-18**)

-59-



step 1 - A suspension of **64** (3.091 g, 0.013 mmol), Mg turnings (0.313 g, 0.013 mmol) in THF (5 mL) was heated at reflux for 45 min then cooled to RT. A solution of **90** (0.350 g, 0.003 mmol) and THF (5 mL) was added and the resulting mixture was heated at reflux for 5 h. The reaction mixture was cooled to RT, quenched with sat'd. NH_4Cl (20 mL) and the resulting solution extracted with EtOAc (100 mL). The combined organic phase was washed with brine, dried (Na_2SO_4), filtered and evaporated. The crude product was purified by SiO_2 chromatography eluting with an EtOAc/hexane gradient (0 to 50% EtOAc) to afford 0.4810 g of **92a**.


step 2 - A flask was charged with **92a** (0.476 g, 2 mmol) and HOAc (3.0 mL) and Br_2 (0.23 mL) was added dropwise. The resulting solution was heated to 70 °C for 5 h., cooled to RT, poured into ice and water (10 mL) and extracted with DCM (10 mL). The organic extract was washed with brine. The organic extract was washed with brine (10 mL) and the combined aqueous fractions again extracted with DCM. The combined organic extracts were dried (Na_2SO_4), filtered and concentrated. The crude product was purified by SiO_2 chromatography eluting with an EtOAc/hexane gradient (0 to 60% EtOAc) to afford 0.12 g (19.7%) of **96b**.

Step 3 was carried out in accord with step 5 of example 5 to afford **I-18**. The crude product was purified by SiO_2 chromatography eluting with an EtOAc/hexane gradient (0 to 60% EtOAc).

Example 9

N-(4-{(E)-2-[3,3-Dimethyl-7-(3-oxo-2,3-dihydro-pyridazin-4-yl)-2,3-dihydro-benzofuran-5-yl]-vinyl}-phenyl)-methanesulfonamide (I-21)

-60-



step 1 – To a solution of **94** (2.457 g, 14 mmol) and acetone (75 mL) was added K_2CO_3 (4.907 g, 36 mmol) and 3-bromo-2-methyl propene (2.0 mL, 20 mmol) and the resulting solution was heated at reflux overnight. The reaction mixture was cooled and concentrated *in vacuo*. The residue was partitioned between EtOAc (150 mL) and H_2O (40 mL). The aqueous phase was extracted with EtOAc and the combined organic extracts were sequentially washed with H_2O and brine, dried (Na_2SO_4), filtered and concentrated *in vacuo*. The residue was purified by SiO_2 chromatography eluting with a EtOAc/hexane gradient (0 to 5% EtOAc) to afford 3.34 g (98.5%) of **96**.

step 2 – To a solution of **96** (3.33 g, 15 mmol) and benzene (150 mL) in a dried flask was added sequentially Bu_3SnH (6.625 g, 22 mmol) and AIBN (0.241 g) and the resulting solution heated at reflux overnight. The reaction mixture was cooled to RT, a 10% KF solution was added and the resulting two-phase mixture stirred vigorously for 2 h. The phases were separated and the organic phase was sequentially washed with sat'd NaHCO_3 (50 mL) and brine. The combined organic extracts were dried (Na_2SO_4), filtered and evaporated. The crude product was purified by SiO_2 chromatography eluting with a DCM/hexane gradient (0 to 10% DCM) to afford 1.855 g (85%) of **98**.

step 3 – To a solution of iodine (2.055 g, 8 mmol) and EtOH (30 mL) was added a solution of silver sulfate (2.525 g, 8 mmol) and a solution of **98** (1.200 g, 8 mmol) in EtOH (10 mL). The

brown solution was stirred for 2.5 h at RT. The resulting suspension was filtered through CELITE, the pad rinsed with EtOH and the filtrate concentrated. The crude product was purified by SiO₂ chromatography eluting with a DCM/hexane gradient (0 to 10% DCM) to afford 2.001 g (90.5%) of **100**.

- 5 step 4 – To a solution of **100** (2.00 g, 7 mmol) and HOAc (18 mL) in a dried flask was cooled to 0 °C and Br₂ was added dropwise over 10 min. The reaction was stirred at RT overnight. Excess bromine was quenched with 10% aq. Na₂S₂O₃ (20 mL) and the HOAc was evaporated. The residue was extracted with Et₂O and the organic extract washed with sat'd. NaHCO₃. The aqueous phase was back-extracted with Et₂O and the combined extracts washed sequentially
10 with NaHCO₃ (2 x 20 mL), H₂O and brine, dried (Na₂SO₄), filtered and concentrated. The residue was purified by SiO₂ chromatography eluting with a DCM/hexane gradient (0 to 10% DCM) to afford 1.5960 g (71.5%) of **102**.

- step 5 – A microwave vial was charged with **72** (0.750 g, 2 mmol, assay 95%), **102** (0.708 g, 2 mmol), K₃PO₄ (1.404 g, 7 mmol) and Pd(PPh₃)₄ (0.127 g, 0.11 mmol) and the tube was
15 evacuated and back-filled with Ar and closed. To the vial was added DMF (10 mL) and the reaction mixture stirred at 80 °C overnight. The reaction mixture was cooled to RT and partitioned between Et₂O (120 mL) and H₂O (20 mL). The aqueous phase was separated and extracted with Et₂O. The combined organic extracts were sequentially washed with H₂O (2 x 20 mL) and brine, dried (Na₂SO₄), filtered and concentrated *in vacuo*. The product was purified by
20 SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 30% EtOAc) to afford 0.4260 g (45.8%) of **104**.

- step 7– A microwave vial was charged with **104** (0.120 g, 0.28 mmol), **108** (0.069 g, 0.31 mmol), Pd(PPh₃)₄ (0.033 g, 0.028 mmol), Na₂CO₃ (0.090 g, 1 mmol), MeOH (3 mL) and DCM (1 mL), flushed with Ar and sealed. The vial was irradiated in a microwave synthesizer for at
25 115 °C for 30 min. The reaction mixture was cooled, concentrated and the residue partitioned between DCM (50 mL) and aq. acetate buffer at pH 4.6. The aqueous layer was extracted with DCM and the combined extracts dried (Na₂SO₄), filtered and evaporated. The crude product was adsorbed onto SiO₂ (1 g) and added to a SiO₂ column that was eluted with an EtOAc/hexane gradient (0 to 70% EtOAc) and the recovered solid triturated with 1 mL of EtOAc/heptane (1:1)
30 and collected to afford **I-21**.


4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-2H-pyridazin-3-one **108** –

A 1L round-bottom flask was charged with 4-chloro-5-hydrazinyl-3(2H)-pyridazinone (8.0 g, 50 mmol), CuSO₄·5H₂O (26.12 g, 10.5 mmol) and H₂O (300 mL) and the mixture was stirred and heated at reflux overnight. The reaction was cooled to 0 °C and an aq. solution of NaOH was added until the pH was 4. The aqueous layer was thrice extracted with EtOAc (500 mL each). The combined extracts were dried (Na₂SO₄), filtered and evaporated. The remaining aqueous phase was adjusted to pH of 2 with 37% HCl and the solution extracted six times with EtOAc. The extracts were combined, dried (Na₂SO₄), filtered and evaporated to afford 4.75 g of 4-chloro-2H-pyridazin-3-one (**110**)

- 10 step 6 - A microwave vial was charged with **110** (0.400 g, 3 mmol), *bis*-(pinacolato)diboron (0.934 g, 4 mmol), dicyclohexyl[2',4',6'-*tris*(1-methylethyl)[1,1'-biphenyl]-2-yl]-phosphine (X-Phos, 0.058 g, 0.12 mmol), Pd₂(dba)₃ (0.056 g, 0.061 mmol) and KOAc (0.902 g, 9 mmol) and the flask was evacuated and back-filled with Ar and sealed. Dioxane (6 mL) was added and the reaction heated at 110 °C overnight. The reaction mixture was cooled to RT and extracted with
- 15 EtOAc (120 mL). The organic extract was washed sequentially with H₂O (10 mL) and brine (10 mL), dried (Na₂SO₄), filtered and evaporated. The crude product was triturated with Et₂O to afford 0.217 g of **108**.

Example 10

- N-(4-{(E)-2-[3,3-Dimethyl-7-(3-oxo-3,4-dihydro-pyrazin-2-yl)-2,3-dihydro-benzofuran-5-yl]-vinyl}-phenyl)-methanesulfonamide (I-23)
- 20



step 1 – A dried flask was charged **104** (0.250 g, 1 mmol), *bis*-(pinacolato)diboron (0.165 g, 1 mmol), PdCl₂(dppf)·DCM (0.097 g, 0.12 mmol), KOAc (0.174 g, 1.7 mmol) and DMSO (16

mL) and the flask was heated at 85 °C overnight. The reaction mixture was cooled to RT and partitioned between H₂O (10 mL) and EtOAc (100 mL). The organic layers were washed five times with H₂O, then once with brine, dried (Na₂SO₄), filtered and evaporated. The crude product was purified on a SiO₂ column eluting with an EtOAc/hexane gradient (0 to 30%

5 EtOAc) to afford 0.108 g (39%) of **110**.

step 2 - A microwave vial was charged **110** (0.099 g, 0.211 mmol), **114** (0.060 g, 0.27 mmol), Pd(PPh₃)₄ (0.024 g, 0.12 mmol), Na₂CO₃ (0.067 g, 0.631 mmol), MeOH (3 mL) and DCM (1 mL) and the flask was heated at 85 °C overnight. The tube was flushed with Ar, sealed and irradiated in a microwave synthesizer at 115 °C for 40 min. The reaction was cooled to RT and
10 partitioned between DCM and H₂O. The combined organic layers were washed with brine, dried (Na₂SO₄), filtered and evaporated. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 40% EtOAc) to afford 0.063 g (56.6%) of **112**.


step 3 - A round-bottom flask was charged with **112** (0.081 g), HOAc (2.5 mL) and 48% HBr (50 µL) and the resulting solution stirred at RT for 7 h. The reaction mixture was poured into a
15 mixture of ice and H₂O and solid NaHCO₃ was added until the effervescence ceased. The solution was extracted with DCM (50 mL) and the organic extract washed with brine, dried (Na₂SO₄), filtered and evaporated. The residue was adsorbed onto 1 g of SiO₂ which was applied to a SiO₂ column and eluted with a MeOH/DCM gradient (0 to 10% MeOH) to afford 43 mg (64%) of **I-23**.

20 2-benzyloxy-3-chloropyrazine (114) – To a solution of 2,3-dichloro-pyrazine (50.0 g, 0.335 mol), benzyl alcohol (39.9 g) and THF (250 mL) was added solid KOH. A slow exotherm occurred which raised the temperature to around 40 °C. The reaction was maintained at 40-45 °C until the reaction was complete. The salts were washed with water, the THF evaporated and **114** purified by simple distillation.

Example 11

25 N-[3-tert-Butyl-2-methoxy-5-(3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-4-(2,2,2-trifluoroethylamino)-benzamide (**I-20**)

-64-



4-(2,2,2-Trifluoro-ethylamino)-benzoic acid (**126**)

step a – To a solution of 4-amino-benzoic acid (2.9 g, 21.15 mmol) in TFA (10 mL) cooled to 0 °C was added trifluoroacetic anhydride (3 mL, 21.24 mmol) and the resulting solution stirred for 1 h. The reaction mixture was poured onto ice (300 mL) and the white precipitate filtered, washed with H₂O and air dried to afford 4.83 g (98%) of 4-(2,2,2-trifluoro-acetyl-amino)-benzoic acid (**120**).

step b To a solution of **120** (4.29 g, 18.40 mmol) in MeOH (50 mL) and toluene (75 mL) was added dropwise trimethylsilyldiazomethane (15.64 mL, 31.3 mmol) until the yellow color persisted. The resulting solution was stirred for 30 min then the reaction was quenched with several drops of HOAc until the yellow color disappeared. The solvents were evaporated to afford methyl 4-(2,2,2-trifluoro-acetyl-amino)-benzoate (**122**) which was used in the next reaction without further purification.

step c – A vial was charged with **122** (1.0 g, 4.05 mmol) and DCM (15 mL) then tetrabutylammonium borohydride was added. The vial was capped and heated overnight in an oil bath at 50 °C. The reaction mixture was cooled to RT and the DCM was evaporated. HOAc was added dropwise until H₂ evolution ceased. The solvents were evaporated and toluene was added. The mixture was made basic with dilute NaHCO₃, extracted with EtOAc, dried (MgSO₄), filtered and evaporated. The resulting solid was recrystallized from hexane to afford 0.349 g of methyl 4-(2,2,2-trifluoro-ethyl-amino)-benzoate (**124**).

step d - To a solution of **124** (0.349 g, 1.497 mmol), MeOH (3 mL), H₂O (1 mL) was added KOH (0.420 g, 7.48 mmol) and the resulting solution was heated at reflux for 1 h. The MeOH was evaporated and the residue diluted with H₂O (15 mL) and acidified to pH of 2 with 6N HCl. The white precipitate was filtered, washed with H₂O and air dried to afford 0.278 g (85%) of

126.

-65-

step 1 - To a solution of **66a** (0.217 g, 0.741 mmol) in HOAc (1.5 mL) is added dropwise, HNO_3 (0.663 mL, 14.82 mmol) and the reaction stirred at RT for 2 h. The resulting mixture was poured onto a mixture of ice and H_2O , twice extracted with EtOAc. The combined extracts were dried (MgSO_4), filtered and evaporated. The crude product was purified by SiO_2

5 chromatography eluting with an EtOAc/hexane gradient (0 to 30% EtOAc) to afford 0.067 g (26.8%) of **116**.

step 2 - A mixture of **116** (0.067 g, 0.198 mmol), KOH (0.014 g, 0.248 mmol), Pd/C (50% H_2O) (0.042 g) and MeOH (5 mL) was stirred under 1 atmosphere of H_2 for 1 h. The catalyst was filtered and evaporated. The residue was partitioned between H_2O and EtOAc. The aqueous

10 phase was again extracted with EtOAc and the combined organic extracts were dried (MgSO_4), filtered and concentrated *in vacuo* to afford 47 mg of **118** as an orange solid.


step 3 - A solution of **118** (0.047 g, 0.172 mmol), **126** (0.041 g, 0.189 mmol) HATU (0.078 g, 0.206 mmol), DIPEA (0.060 mL) and dry DMF (3 mL) was stirred at 60 °C under Ar for 5 d. The reaction was diluted with H_2O and twice extracted with EtOAc. The combined extracts

15 were washed with H_2O , dried (MgSO_4), filtered and evaporated. The crude product was purified on a preparatory SiO_2 TLC plate developed twice with 7% MeOH/DCM to afford 13 mg of **I-20** as a yellow foam.

Example 12

4-Amino-N-[3-tert-butyl-2-methoxy-5-(3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-benzamide

20 (I-19)



step 1 - A microwave vial was charged with **66b** (0.10 g, 0.297 mmol), 4-nitro-benzamide (0.049 g, 0.297 mmol), CuI (5365 mg, 0.030 mmol), K_2CO_3 (0.082 g, 0.593 mmol), N,N'-dimethyl-ethylenediamine (5.23 mg, 0.059 mmol) and toluene (1.5 mL). The vial was flushed with Ar, sealed and heated at 90 °C overnight. The reaction mixture was cooled, diluted with H_2O and

25


-66-

twice extracted with EtOAc. The combined extracts were dried (MgSO₄), filtered and concentrated *in vacuo*. The crude product was adsorbed on SiO₂ and applied to a SiO₂ column and eluted with an EtOAc/hexane gradient (0 to 20% EtOAc) to afford 35.8 mg of **128**.

step 2 - A mixture of **128** (0.052 g, 0.012 mmol), Pd/C (26 mg, 50% H₂O), EtOAc (5 mL) and MeOH was hydrogenated at atmospheric pressure overnight. The solution was filtered through CELITE and the filtrate evaporated. The crude product was purified on a preparative SiO₂ TLC plate developed with 5% MeOH/DCM to afford 14 mg of **I-19**.

Example 13

N-(4-{(E)-2-[3-tert-Butyl-2-methoxy-5-(6-oxo-1,6-dihydro-pyrimidin-5-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide (**I-22**)




4-benzyloxy-5-bromo-pyrimidine (132) – To a suspension of 5-bromo- 4(3H)-pyrimidinone (1.00 g, 5.6 mmol, CASRN 19808-30-1), 50% silver carbonate on CELITE (3.467 g, 6 mmol) and toluene (30 mL) was added benzyl bromide (0.75 mL, 6 mmol) and the resulting mixture heated at 125 °C for 1 h. The reaction was cooled and filtered through a glass microfiber filter which was rinsed with toluene. The filtrate was evaporated and the residue purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 10% EtOAc) to afford 0.140 g of **132**,

step 1 - Suzuki coupling of **132** and **86** was carried out in accord with the procedure described in step 5 of example 1. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 50% EtOAc) to afford **130**.

step 2 – The debenzoylation of **130** was carried out in accord with the procedure described in step 7 of example 1. The crude product was triturated with EtOAc/Et₂O to afford **I-22**.

Example 14


2-{2-[3-tert-Butyl-5-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-phenyl]-ethyl}-5-methanesulfonylamino-benzoic acid methyl ester (142)



- 5 step 1 – To a mixture of the **84c** (100 mg, 0.23 mmol), **137** (53 mg, 0.34 mmol, CASRN 70523-22-7), Na₂CO₃ (73 mg, 0.69 mmol) in MeOH (3 mL) and DCM (1 mL) was added the Pd(PPh₃)₄ (26 mg, 0.023 mmol). The solution mixture was purged with Argon for two min and then irradiated in a microwave synthesizer at 110 °C for 40 min. TLC and LCMS analyses of an aliquot showed product and starting bromide. The reaction mixture was cooled to RT, diluted
- 10 with DCM and filtered through CELITE. The filtrate was concentrated and the crude mixture was purified on a preparative TLC plate developed with 6% MeOH/DCM to afford 7.4 mg of **I-25**.

Example 15

- N-(4-{(E)-2-[3-Cyclopropyl-2-methoxy-5-(3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide (**I-26**)
- 15



- step 1 – To a solution of **140a** (0.438 g, 3.3 mmol) and MeCN (7 mL) was added paraformaldehyde (0.661 g 22 mmol), MgCl₂ (0.466 g, 4.9 mmol) and TEA (1.78 mL, 12 mmol) and the resulting suspension stirred at reflux for 7 h. (N. Gisch *et al.*, *J. Med. Chem.* 2007
- 20 50(7):1658) The reaction mixture was cooled to RT and partitioned between DCM (100 mL) and 1N HCl (20 mL). The aqueous layer was extracted with DCM and the combined DCM

extracts were dried (Na_2SO_4), filtered and evaporated. The crude product was purified by SiO_2 chromatography eluting with an EtOAc/hexane gradient (0 to 5% EtOAc) to afford 0.3940 (74.4%) of **140b**.

step 2 – Bromination of **140b** was carried out with tetrabutylammonium tribromide in accord with the procedure described in step 5 of example 4 to afford **142a** which was purified by SiO_2 chromatography eluting with an EtOAc/hexane gradient (0 to 5% EtOAc).

step 3 – O-Methylation of **142a** was carried out in accord with the procedure described in step 6 of example 4 to afford **142b** which was used without additional purification.

step 4 – Condensation of **142b** and diethyl 4-nitro-benzyl-phosphonate was carried out in accord with the procedure described in step 1 of example 1 to afford **144a** which was purified by SiO_2 chromatography eluting with an EtOAc/hexane gradient (0 to 10% EtOAc).


step 5 – To a suspension of **144a** (0.630 g, 1.68 mmol), MeOH (12 mL) and H_2O (12 mL) was added NH_4Cl (0.900 g, 17 mmol) and iron powder (0.451 g, 8.1 mmol, <10 micron) and the resulting mixture was heated and stirred overnight at reflux. The reaction mixture was cooled to RT and filtered through a glass microfiber filter which was rinsed with MeOH/EtOAc/DCM. The filtrate was concentrated and partitioned between DCM (100 mL) and H_2O (15 mL). The organic extract was washed with brine and the brine was back extracted with DCM. The combined DCM extracts were dried (Na_2SO_4), filtered and evaporated to afford 0.55 g (94.9%) of **144b** which was used in the next step without additional purification.

step 6 – Conversion of **144b** to the sulfonamide **144c** was carried out in accord with the procedure described in step 3 of example 1. **144c** was purified by SiO_2 chromatography eluting with an EtOAc/hexane gradient (0 to 30% EtOAc).

step 7 – Palladium-catalyzed coupling of **108** and **144c** was carried out in accord with the procedure described in step 7 of example 9 to afford **I-26** which was purified by SiO_2 chromatography eluting with an EtOAc/hexane gradient (0 to 80% EtOAc).

Example 16

N-(4-{{(E)-2-[4-Methoxy-3,3-dimethyl-7-(3-oxo-2,3-dihydro-pyridazin-4-yl)-2,3-dihydro-benzofuran-5-yl]-vinyl}-phenyl}-methanesulfonamide (**I-27**)



- 5 step 1 – Alkylation of **146** with 3-bromo-2-methyl-propene was carried out in accord with the procedure in step 1 of example 9 to afford **148** which was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 10% EtOAc).

- step 2 – A dried round-bottom flask was charged with **148** (3.720 g, 15 mmol), benzene (150 mL), tributyltin hydride (6.695 g, 22 mmol) and AIBN (0.251g, 2 mmol) and the reaction mixture was heated at reflux overnight. The reaction mixture was cooled to RT and a 10% aq. KF solution was added and the resulting two-phase mixture stirred vigorously for 3.5 h. The phases were separated and the aqueous layer was extracted with EtOAc (150 mL). The organic phase was washed with brine, dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 10% EtOAc) to afford 2.53 g (90.6%) of **150**.

- step 3 - To a solution of iodine (3.091 g, 12 mmol) and EtOH (40 mL) was added Ag₂SO₄ (3.798 g, 0.12 mmol) and **150** (1.00 g, 6 mmol). The brown suspension was stirred at RT for 2 h. The mixture was filtered through a pad of CELITE and pad was washed with EtOAc/EtOH. The filtrate was concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 10% EtOAc) to afford 1.71 g (68%) of **152a**.

step 4 - O-Methylation of **152a** was carried out in accord with the procedure described in step 6 of example 4 to afford **152b** which was used without additional purification.

step 5 - Palladium-catalyzed coupling of **108** and **152b** was carried out in accord with the procedure described in step 7 of example 9. The crude product was purified by SiO₂


5 chromatography eluting with an EtOAc/hexane gradient (0 to 40% EtOAc) to afford 49 mg (15%) of **154**.

step 6 - A microwave vial was charged with **154** (0.049 g, 0.12 mmol), **156** (0.039 g, 0.16 mmol, CASRN 1132942-08-5), Na₂CO₃ (0.039 g, 0.37 mmol), Pd(PPh₃)₄ (0.014 g, 0.012 mmol), MeOH (1.4 mL) and toluene (0.7 mL). The vial was flushed with argon, sealed and irradiated in
10 a microwave synthesizer at 120° C for 1 h. The reaction mixture was cooled and partition between DCM (50 mL) and NaOAc buffer adjusted to pH 4.6. The aqueous buffer was extracted with DCM and the combined organic extracts were dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 60% EtOAc) to afford 43 mg (74.7%) of **I-27**.

15 **I-28** was prepared analogously except in step 5, **108** was replaced with **137** to afford N-(4-{{(E)-2-[7-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-4-methoxy-3,3-dimethyl-2,3-dihydro-benzofuran-5-yl]-vinyl}-phenyl)-methanesulfonamide which was purified by SiO₂ chromatography and eluted with a gradient of DCM and a solution of 10% MeOH/DCM/0.5% NH₄OH (0 to 50%). The recovered product was rechromatographed using the same gradient
20 then recovered and triturated with MeOH to afford **I-28**.

Example 17

N-(6-{{(E)-2-[3-*tert*-Butyl-5-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-phenyl]-vinyl}-pyridin-3-yl)-methanesulfonamide (**I-29**)



step 1 – To a solution of **158 a** (1.0 g, 6.553 mmol, CASRN 36625-57-7) in DCM (40 mL) cooled to 0 °C was added sequentially TEA (1.2 mL, 8.518 mmol) and methanesulfonyl chloride (0.56 mL, 7.208 mmol). After 30 min the solution was washed with H₂O and the organic phase dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with 40% EtOAc/hexane to afford 1.44 g (95%) of **158b** as a yellow solid.

step 2 – To a solution of **158b** (1.44 g, 6.218 mmol) in THF (20 mL) was added LiBr (0.594 g, 6.840 mmol). After stirring for 2 h at RT the reaction mixture was diluted with EtOAc, washed sequentially with H₂O and brine. The organic extract was dried (Na₂SO₄), filtered and concentrated *in vacuo* to afford an orange oil which was dissolved in THF (5 mL) and trimethylphosphite (5 mL) was added. The solution was warmed to 100 °C for 5 h then concentrated. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/MeOH gradient (0 to 5% MeOH) to afford 1.72 g of **158c** as an orange oil.


Condensation of **158c** and **28** (step 3) was carried out in accord with the procedure described in step 1 of example 1 to afford **160a**. Reduction of the nitro group (step 4) was carried out with iron powder as described in step 5 of example 15 and the product was purified by SiO₂ chromatography eluting with 40% EtOAc/hexane to afford **160b**. Sulfonylation of **160b** (step 5) was carried out as described in step 3 of example 1 and the crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (20 to 80% EtOAc) to afford **160c**.

Palladium-catalyzed coupling of **160c** and **137** was carried out in accord with the procedure described in example 14. The crude product was purified by SiO₂ chromatography eluting with 10% MeOH/DCM. The product co-eluted with uracil and the solid was stirred in hot H₂O for several hours. The hot slurry was filtered and washed with Et₂O and dried *in vacuo* overnight to afford N-(6-((*E*)-2-[3-*tert*-butyl-5-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-phenyl]-vinyl)-pyridin-3-yl)-methanesulfonamide (**I-29**).

Example 18

[0100] N-(4-((*E*)-2-[3-(1-Difluoromethyl-cyclopropyl)-5-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-phenyl]-vinyl)-phenyl)-methanesulfonamide (**I-30**)

-72-



step 1 - To a solution of 5-bromosalicylaldehyde (**162a**, 10.0 g, 49.7 mmol) in DMF (100 mL) at RT was added K₂CO₃ (13.7 g, 99.4 mmol) followed by chloromethyl methyl ether (tech grade, 5.2 mL, 54.7 mmol). The reaction mixture was stirred at RT overnight then quenched with H₂O and thrice extracted with EtOAc. The organic phase was thrice washed with H₂O, dried (MgSO₄) and concentrated to afford 11.6 g (96%) of **162b** as a yellow oil.

step 2 - To a solution of **162b** (11.6 g, 47.3 mmol) in MeOH (100 mL) at 0 °C was slowly added NaBH₄ (1.87 g, 49.6 mmol). The reaction mixture was stirred at 0 °C for 1 h then quenched with H₂O and brine. The organic phase was thrice extracted with EtOAc, dried (MgSO₄), filtered and concentrated to afford 11.3 g (97%) of **164a** as a pale yellow oil.

step 3 - To a solution of alcohol **164a** (10.0 g, 40.5 mmol) in DCM (80 mL) cooled to 0 °C was added TEA (7.3 mL, 52.6 mmol) and methanesulfonyl chloride (3.4 mL, 44.5 mmol). The reaction mixture was stirred for 1 h then quenched with H₂O and extracted with DCM. The organic extracts were dried (MgSO₄), filtered and concentrated to a light yellow oil. To a solution of this oil in DMF (50 mL) was added LiBr (3.9 g, 44.5 mmol) and the reaction mixture was stirred at RT for 1 h. A solution of NaCN (3.0 g, 60.7 mmol) in H₂O (5 mL) was slowly added, using an ice bath to control the exothermic reaction. After the addition was complete, the reaction mixture was stirred at RT for 1 h then quenched with H₂O and thrice extracted with EtOAc. The organic phase was thrice washed with H₂O then dried (MgSO₄), filtered and concentrated to afford 10.5 g of **164b** as a yellow oil.

-73-

step 4 - To a solution of **164b** (2.6 g, 10.1 mmol) in DMF (25 mL) cooled to 0 °C was added NaH (60% in mineral oil, 0.89 g, 22.2 mmol). The reaction mixture was stirred at 0 °C for 0.5 h then 1,2-dibromoethane (0.96 mL, 11.1 mmol) was added dropwise. The reaction mixture was warmed to RT and stirred for 1 h then quenched with H₂O and thrice extracted with EtOAc. The combined organic extracts were thrice washed with H₂O then dried (MgSO₄), filtered and concentrated. The residue was purified by SiO₂ chromatography eluting with 10% EtOAc/hexanes to afford 1.83 g (64%) of **166a** as a yellow oil.

step 5 - To a solution of nitrile **166a** (1.83 g, 6.5 mmol) in DCM (40 mL) cooled to -78°C was added DIBAL-H (1.27 mL, 7.1 mmol) dropwise. The reaction mixture was stirred at -78 °C for 2 h then quenched with MeOH (0.5 mL) and warmed to RT. A saturated solution of Rochelle's salt (40 mL) was added and the biphasic mixture was stirred vigorously for 30 min. The phases were separated and the aqueous phase was extracted with DCM. The combined organic extracts were dried (MgSO₄), filtered and concentrated. The crude residue was purified by SiO₂ chromatography eluting with 2% EtOAc/DCM to afford 1.49 g (81%) of **166b** as a pale yellow oil.

step 6 - To a solution of **166b** (4.9 g, 17.2 mmol) in DCM (80 mL) was slowly added (diethylamino)sulfur trifluoride (6.8 mL, 51.6 mmol). The reaction mixture was stirred at RT overnight then quenched by slowly pouring onto ice. The mixture was diluted with H₂O and extracted with DCM. The combined organics were dried (MgSO₄), filtered and concentrated. The crude residue was purified by SiO₂ chromatography eluting with 10% EtOAc/hexanes to afford 4.07 g (77%) of **166c** as a colorless oil.

step 7 - To a solution of **166c** (4.05 g, 13.2 mmol) in DCM (60 mL) cooled 0°C was added 4Å powdered molecular sieves (4 g) followed by bromotrimethylsilane (5.2 mL, 39.6 mmol). The reaction mixture was allowed to warm to RT and stirred overnight then filtered to remove the sieves which were rinsed with DCM. The filtrate was washed sequentially with sat'd. aq. NaHCO₃ and H₂O then dried (MgSO₄), filtered and concentrated. The crude residue was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (10% to 20% EtOAc) to afford 2.85 g (82%) of **168a** as a pale yellow oil.

step 8 - To a solution of **168a** (2.85 g, 10.8 mmol) in anhydrous MeCN (50 mL) was added TEA (5.6 mL, 40.5 mmol), MgCl₂ (1.54 g, 16.2 mmol), and paraformaldehyde (2.27 g, 75.6 mmol).


The bright yellow reaction mixture was heated at reflux for 5 h then cooled to RT and quenched with 1.0 M aqueous HCl. The mixture was thrice extracted with EtOAc then the combined organics were dried (MgSO₄), filtered and concentrated. The crude residue was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (10% to 20% EtOAc) to afford 1.04 g (33%) of **168b** as an off-white solid.

step 9 - To a solution of **168b** (1.04 g, 3.6 mmol) in DMF (15 mL) was added K₂CO₃ (1.0 g, 7.2 mmol) followed by iodomethane (0.27 mL, 4.3 mmol). The reaction mixture was stirred at RT for 4 h then quenched with H₂O and thrice extracted with EtOAc. The combined extracts were thrice washed with H₂O, dried (MgSO₄), filtered and concentrated to afford 1.06 g (97%) of **170** as a pale yellow solid which required no further purification.

steps 10-12 – Condensation of **170** with diethyl 4-nitro-benzyl-phosphonate (step 10), reduction of the nitro group (step 11) and sulfonylation of the amine (step 12) can be carried out in accord with the procedures in steps 1-3 of example 1 to afford **172**. Palladium-catalyzed coupling of **172** and **137** is carried out in accord with the procedure in example 14.

Example 19

N-(4-{(E)-2-[3-(1-Difluoromethyl-cyclopropyl)-2-methoxy-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide (**I-31**)



step 1 – A suspension of **172** (0.215 g, 0.455 mmol), bis-(pinacolato)diboron (0.127 g, 0.501 mmol), KOAc (0.134 g, 1.37 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (0.011 g, 0.0137 mmol), dppf (0.008 g, 0.0137 mmol) and dioxane (3 mL) were stirred overnight at 100° C. The reaction mixture was cooled to RT and quenched with H₂O and extracted with EtOAc. The organic extract was dried (MgSO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂

chromatography eluting with an EtOAc/hexane gradient (10 to 50% EtOAc) to afford 255 mg (95%) of **174** as a colorless oil which contained about 7% of bis-(pinacolato)diboron.

step 2 – A microwave vial was charged with **174** (0.236 g, 0.454 mmol), 2-benzyloxy-3-chloro-pyrazine (0.110 g, 0.50 mmol), Pd(PPh₃)₄ (26 mg, 0.0227 mmol), Na₂CO₃ (96 mg, 0.909 mmol),
5 MeOH (2 mL) and DCM (0.5 mL), sealed and irradiated in a microwave synthesizer at 115 °C for 0.5 h. An addition aliquot of the pyrazine (40 mg) was added and heated continued for another 20 min. The reaction mixture was cooled to RT, diluted with DCM and sequentially washed with H₂O and brine. The aqueous phase was back extracted with DCM. The combined DCM extracts were dried (MgSO₄), filtered and concentrated *in vacuo*. The crude product was
10 purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (10 to 50% EtOAc) to afford 190 mg (60%) of **176** as a white foam.

step 3 – To a solution of **176** (0.190 g, 0.329 mmol) and HOAc (3 mL) was added 48% HBr (0.11 mL) and the resulting solution was stirred and heated to 52 °C for 1.5 h. The mixture was cooled to RT and carefully added to sat'd. aq. NaHCO₃. The mixture was diluted with EtOAc
15 which resulted in the formation of a precipitate in the organic layer that was filtered and twice washed with sat'd. aq. NaHCO₃. The filtrate was concentrated to afford a yellow solid which was triturated with EtOAc. The solids were combined to afford 0.111 g (85%) of **I-31** as a yellow solid.

Example 20

20 N-(4-{(E)-2-[3-*tert*-Butyl-5-(2-chloro-6-oxo-1,6-dihydro-pyrimidin-5-yl)-2-methoxy-phenyl]-vinyl}-phenyl)-methanesulfonamide (**I-32**)

Palladium-catalyzed coupling of 2-chloro-4-(phenylmethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyrimidine (149 CASRN 1073354-22-9) and **84c** was carried out in accord with the procedure described in example 14 to afford N-(4-{(E)-2-[5-(4-benzyloxy-2-chloro-pyrimidin-5-yl)-3-*tert*-butyl-2-methoxy-phenyl]-vinyl}-phenyl)-methanesulfonamide. Cleavage
25 of the benzyl group was carried out in accord with the procedure in step 3 of example 19. The crude product was purified on a preparative SiO₂ plate developed with 5% MeOH/DCM to afford **I-32**.


N-(4-{(E)-2-[3-*tert*-Butyl-5-(2-dimethylamino-6-oxo-1,6-dihydro-pyrimidin-5-yl)-2-methoxy-phenyl]-vinyl}-phenyl)-methanesulfonamide (**I-33**) was prepared analogously except in step 1,
30

4-benzyloxy-2-chloro-pyrimidin-5-yl boronic acid was replaced with 4-benzyloxy-2-dimethylamino-pyrimidin-5-yl boronic acid (CASRN 205672-21-5).

N-(4-{{(E)-2-[3-*tert*-Butyl-2-methoxy-5-(2-methoxy-6-oxo-1,6-dihydro-pyrimidin-5-yl)-phenyl]-vinyl}-phenyl} -methanesulfonamide (**I-34**) was prepared analogously except in step 1, 4-benzyloxy-2-chloro-pyrimidin-5-yl boronic acid was replaced with 2,4-dimethoxy-pyrimidin-5-yl boronic acid (CASRN 89641-18-9).

Example 21

N-(4-{{(E)-2-[3-*tert*-Butyl-2-methoxy-5-(6-oxo-1,6-dihydro-[1,2,4]triazin-5-yl)-phenyl]-vinyl}-phenyl)-phenyl)-methanesulfonamide (**I-36**)



step 1 – To a suspension of AlCl₃ (4.19 g, 31 mmol) and DCM (25 mL) cooled to 0 °C and maintained under nitrogen was added dropwise over 10 min ethyl chloroformate (4.24 g, 31 mmol) and the resulting solution was stirred for an additional 15 min. To the resulting solution was added dropwise over 15 min *via* syringe **180a** (4.0 g, 16.5 mmol, CASRN 1007375-07-6). The resulting solution was allowed to warm to RT and stirring was continued for 1.5 h. The solution was poured into a mixture of ice (150 g) and con HCl (50 mL) and the resulting mixture extracted with DCM (3 x 50 mL). The combined organic extracts were washed with dilute NaOH, then twice with brine, dried (Na₂SO₄), filtered and concentrated in vacuo. The crude product was purified by SiO₂ chromatography eluting with 10% EtOAc/hexane to afford 4.22 g (74%) of **180b**.

step 2 – A solution of **180b** (4.2 g, 12.2 mmol), hydroxylamine hydrochloride (1.36 g, 19.6 mmol), NaOAc (1.1 g, 14.5 mmol) and EtOH (65 mL) was heated to reflux for 3 h, cooled, concentrated and partitioned between EtOAc and H₂O. The EtOAc extract was washed with brine, dried (Na₂SO₄), filtered and concentrated *in vacuo* to afford 4.5 g (99 %) of **180c** as a white solid.

step 3 – A solution of **180c** (4.4 g, 12.3 mmol) and MeOH (25 mL)/H₂O (15 mL)/ HCO₂H (15 mL) cooled in an ice-water bath was added portion wise over 1 h, Zn dust 1.61 g, 24.6 mmol). (S. Kukolja, et al., J. Med. Chem. 1985 28:1886) The solution was stirred at 0 °C for 7 h, removed from the ice bath and stirred an addition 2 h. TLC analysis of the mixture indicated only partial transformation occurred and another aliquot of Zn (0.8 g, 1, eq.) was added and the reaction stirred for 40 h at RT. The mixture was filtered through CELITE and the pad washed with MeOH. The filtrate was concentrated, dilute HCl was added and the solution was extracted with EtOAc. The EtOAc layer was washed with 1N NaOH, dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (75 to 100% EtOAc) to afford 2.9 g (67%) of **182** as a white solid.

step 4 – To a solution of **182** (2.7 g, 8.0 mmol) and DMF (50 mL) was added dimethoxymethyl-dimethyl-amine (1.42 g, 12 mmol) and the resulting solution stirred overnight at RT. The reaction mixture was concentrated *in vacuo* and finally subjected to a high vacuum for 2 h to afford **184** which used without additional purification.

step 5 – To a solution of **184** (3.2 g, 8.0 mmol) and EtOH (25 mL) was added hydrazine (0.5 mL, 15.9 mmol) and the resulting solution was heated to reflux for 2 h. The solution was cooled to RT and concentrated *in vacuo* and purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (50 to 100% EtOAc) to afford 1.7 g (63%) of **186** as a white solid.

step 6 – To a solution of **186** (1.0 g, 2.9 mmol) in CHCl₃ (7.5 mL) and MeOH (7.5 mL) was added NaOAc (0.29 g, 3.5 mmol) and the resulting solution cooled in an ice/MeOH bath. To this solution was added bromine (0.34 g, 2.2 mol) dropwise over 1 to 2 min. After approximately 1 min, starting material appeared to have been consumed (TLC) and the reaction was quenched with aq. Na₂CO₃ and extracted with CHCl₃. The combined extracts were dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography

eluting with an EtOAc/hexane gradient (50 to 100% EtOAc) to afford 0.58 g (77%) of **188** as a yellow solid.

step 7 - Palladium-catalyzed coupling of **188** and **156** was carried out in accord with the procedure described in step 6 of example 16 except Pd(PPh₃)₄ was replaced with 1,1'-bis(di-*tert*-butylphosphino)ferrocene palladium dichloride. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 100% EtOAc) to afford **I-36**.

Example 22


N-{6-[3-*tert*-Butyl-2-methoxy-5-(6-oxo-1,6-dihydro-[1,2,4]triazin-5-yl)-phenyl]-naphthalen-2-yl}-methanesulfonamide (**I-37**)

- 10 A microwave tube was charged with **186** (0.064 g, 0.19 mmol), N-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthalenyl]-methanesulfonamide (0.13 g, 0.37 mmol, CASRN 1132940-88-5), Pd(PPh₃)₄ (0.005 g, 0.004 mmol), Na₂CO₃ (0.020 g, 0.19 mmol), PhMe (1 mL) and MeOH (1 mL) and irradiated at 115° C for 1 h. The reaction was cooled and the crude product suspended in CHCl₃ and adsorbed on a SiO₂ column and eluted with an EtOAc/hexane gradient
- 15 (50 to 100% EtOAc to a solution of 1%HOAc/EtOAc) which afforded a solid which was triturated with Et₂O/hexane and filtered to afford 8 mg of **I-37**.

Example 23

N-(4-{{(*E*)-2-[3-*tert*-Butyl-2-methoxy-5-(2-methoxy-6-oxo-1,6-dihydro-pyrimidin-5-yl)-phenyl]-vinyl}-3-methoxymethyl-phenyl)-methanesulfonamide (**I-39**)

-79-



step 1 – A solution of **28** (4.17 g, 15.39 mmol), **188** (2.00 g, 10.26 mmol), DBU (3.1 mL, 20.73 mmol) and DMSO (10 mL) was stirred overnight at RT then heated to 50 °C for 1 h. To the solution was added 1N NaOH and the resulting solid filtered. The filtrate was acidified with 6N HCl extracted with EtOAc and the combined extracts were dried (Na₂SO₄), filtered and evaporated to afford 2.51 g of **200a**.

step 2 – A solution of **200a** (2.00 g, 4.608 mmol), iodomethane (1.05 mL, 16.87 mmol), K₂CO₃ (1.92 g, 13.89 mmol) and DMF (10 mL) was stirred overnight at RT. The resulting solution was filtered and the filtrate was diluted with EtOAc and washed with 1N HCl, H₂O and brine. The organic phase was dried (Na₂SO₄), filtered and concentrated *in vacuo* to afford 1.94 g (94%) of **200b**.

step 3 - To a solution of **200b** (500 mg, 1.12 mmol) in THF (10 mL) cooled to 0 °C, was added LiAlH₄ (1.7 mL, 1.7 mmol, 1.0 M solution in THF). The reaction was gradually warmed to RT over 45 min, then re-cooled to 0 °C and quenched with NaHSO₄ solution. The suspension was concentrated, diluted with EtOAc, and washed sequentially with 1N HCl and brine. The organic extract was dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (5% to 10% EtOAc) to afford 129 mg (28%) of {2-[(*E*)-2-(5-bromo-3-*tert*-butyl-2-methoxy-phenyl)-vinyl]-5-nitro-phenyl}-methanol (**200c**) as a yellow oil.

step 4 - To a solution of **200c** (116 mg, 0.276 mmol) in DMF (5 mL) was added sodium hydride (0.022, 0.550 mmol, 60% mineral oil dispersion). After 20 min, methyl iodide (0.040 mL, 0.643 mmol) was added and the resulting suspension was stirred overnight. The reaction mixture was diluted with EtOAc, thrice washed with brine, dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (5% to 15% EtOAc) to afford 81 mg (68%) of **200d** as an orange oil.

Reduction of the nitro group (step 5) was carried out with SnCl₂.2H₂O in DMF/EtOAc in accord with the procedure described in step 2 of Example 1 to afford **202a**. Sulfonylation of the amine to afford **202b** (step 6) is carried out in accord with the procedure described in step 3 of example

step 7 - A tube was charged with **202b** (100 mg, 0.207 mmol), 2,4-dimethoxy-pyrimidin-5-yl boronic acid (207 mg, 0.261 mmol), Pd(PPh₃)₄ (27 mg, 0.023 mmol), Na₂CO₃ (61 mg, 0.576 mmol), MeOH (3 mL) and DCM (1 mL), sealed and irradiated in a microwave synthesizer at 115 °C for 30 min. The reaction mixture was concentrated, diluted with EtOAc, washed with brine, dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (50 to 100% EtOAc) to afford 35 mg (31%) of **204** as a cream colored solid.

step 8 - A solution of **204** (35 mg, 0.065 mmol), 48% HBr (0.05 mL, 0.436 mmol) in HOAc (3 mL) was heated at 60 °C overnight in a sealed tube. The reaction mixture was carefully poured into a mixture of sat'd. aq. NaHCO₃/ice which was extracted with EtOAc. The combined extracts were dried (Na₂SO₄), filtered and dried *in vacuo* to afford **206** which was used in the final step without additional purification.

step 9 - A solution of **206** (0.065 mmol), sodium methoxide (10 mL, 5 mmol, 0.5M in methanol) and methanol (10mL) was stirred at RT overnight. The reaction mixture was concentrated, diluted with EtOAc and acidified with 6N HCl. The combined EtOAc extracts were dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified on a preparatory SiO₂ plate developed with 2:1 EtOAc/hexane to afford 12 mg (34%) of **I-39** as an off-white solid.


Example 24

N-(4-{{(E)-2-[3-*tert*-Butyl-5-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-phenyl]-vinyl}-3-methoxymethyl-phenyl)-methanesulfonamide (**I-40**)

- A sealed tube was charged with **202b** (100 mg, 0.207 mmol), **137** (45 mg, 0.289 mmol),
 5 Pd(PPh₃)₄ (24 mg, 0.21 mmol), Na₂CO₃ (57 mg, 0.537 mmol), MeOH (2 mL), DCM (1mL) and
 DMF (1 mL), sealed and irradiated in a microwave synthesizer at 115 °C for 30 min. LCMS
 analysis indicated *ca.* 60% conversion and additional aliquots of **137** (52 mg, 0.334) and
 Pd(PPh₃)₄ (24 mg, 0.21 mmol) were added and irradiation continued at 115°C for 30 min. The
 reaction mixture was concentrated, diluted with EtOAc, washed with brine, dried (Na₂SO₄),
 10 filtered and concentrated *in vacuo*. The crude product was purified on a preparative SiO₂ plate
 using sequential developments with 2:1 EtOAc/hexane and 3:1 EtOAc/hexane to afford 35 mg
 (33%) of **I-40** as an off-white solid.

Example 25

- N-(4-{{(E)-2-[5-(2,4-Dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-3-trifluoromethoxy-
 15 phenyl]-vinyl}-phenyl)-methanesulfonamide (**I-42**)



- 4,6-dibromo-2-trifluoromethoxy-phenol (208a)** A solution of 2-trifluoromethoxy-phenol (1.0 g, 5.6 mmol, CASRN 32858-93-8), NBS (2.22 g, 12 mmol) and DMF (30 mL) were stirred overnight under a nitrogen atmosphere. The solution was partitioned between EtOAc and H₂O.
 20 The organic extract was dried and concentrated in vacuo to afford **208a** which contained some DMF but was used with additional purification.

- step 1** – A solution of **208a** (6.6 g, 19.37 mmol), iodomethane (3.35 g, 23.64 mmol), K₂CO₃ (8.17 g, 39.1 mmol) was warmed to 55 °C for 2 h cooled to RT, sealed and stirred at RT for 72 h. The reaction mixture was diluted with H₂O and extracted with EtOAc. The combined extracts
 25 were twice washed with H₂O then with brine, dried (MgSO₄), filtered and concentrated *in vacuo*.

The crude product was purified by SiO₂ chromatography eluting with hexanes to afford 5.03 g of **208b**.


step 2 - Palladium-catalyzed coupling of **208b** (1.1 g, 3.15 mmol) and **137** (0.446 g, 0.286 mmol) was carried out in accord with the procedure described in example 14. The crude product was purified by SiO₂ chromatography eluting with 80% EtOAc/hexane to afford 0.577 g of **210** as a white solid.

step 3 – Palladium-catalyzed coupling of **210** and **156** was carried out in accord with the procedure described in step 6 of example 16. The crude product was thrice triturated in hot H₂O, and the liquid decanted. The remaining white solid was filtered and dried to afford 46 mg of **I-**

42.

Example 26

N-(4-{(*E*)-2-[3-*tert*-Butyl-5-(4-hydroxy-2-methyl-6-oxo-1,6-dihydro-pyrimidin-5-yl)-2-methoxy-phenyl]-vinyl}-phenyl)-methanesulfonamide (**I-41**)




step 1 - In a 25 mL round-bottomed flask **84c** (400 mg, 912 mmol), 0.17 mL of diethyl malonate (183 mg, 174 μ L, 1.14 mmol) and potassium phosphate (581 mg, 2.74 mmol) were combined in toluene (3 mL) under argon. To the mixture was added *bis*(tri-*tert*-butylphosphine)palladium(0) (18.7 mg, 36.5 μ mol) to produce a yellow solution which was degassed by bubbling argon through the solution for ca. 5 min. The reaction mixture was heated to 70 $^{\circ}$ C in an oil bath and stirred *ca.* 17 h under an inert atmosphere. The reaction mixture was diluted with EtOAc (25 mL) and poured into 0.4 M HCl (50 mL). The aqueous layer was extracted with EtOAc (1 x 25 mL). The organic layers were combined and washed with satd. aq. NaCl (1 x 75 mL). The organic layer was dried (MgSO₄), filtered and concentrated *in vacuo* to afford 600 mg of a bright yellow oil. The crude material was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (5% to 20% to 40% EtOAc) to afford **212** as a clear oil.

-83-

step 2 - A 25% solution of sodium methoxide in MeOH (1.5 mL) was added to acetamidine hydrochloride (70 mg, 0.74 mmol) in a 25 mL round-bottomed flask and the resulting mixture was stirred at RT for 10 min. A solution of **212** (110 mg, 0.21 mmol) in MeOH (0.3 mL) was added and the reaction was stirred at 50 °C for 12 h and then at RT for 48 hr. The reaction was concentrated in vacuo. The crude product was purified by SiO₂ chromatography elution with a MeOH/DCM gradient (4% to 10% MeOH) to afford **I-41** as a white solid (15%): LCMS: (M+H) = 484; (M-H) = 482; ¹H NMR (DMSO) δ 7.6 (m, 3H); 7.42 (s, br, 1H); 7.7 (m, 3 H); 6.97 (d, br, 1 H); 3.74 (s, OMe); 2.99 (s, 3H); 2.28 (s, 3H); 1.36 (s, t-Bu).

Example 27

- 10 N-(4-{(E)-2-[3-*tert*-Butyl-2-methoxy-5-(2-methyl-6-oxo-1,6-dihydro-pyrimidin-5-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide (**I-43**)



step 1 - To a solution of **214a** (5 g, 28 mmol) and DMF (40 mL) was added in one portion N-iodosuccinimide (8.2 g, 36 mmol). The solution was stirred at RT for 1 h, diluted with H₂O and twice extracted with EtOAc. The combined organic extracts were washed sequentially with H₂O and brine, dried (Na₂SO₄), filtered and concentrated in vacuo to afford **214b** as an oil which was used without further purification.

step 2 - The product from step 1 was dissolved in DMF (25 mL) and iodomethane (3 mL) and K₂CO₃ (3 g) were added. The resulting mixture was heated at 60 °C for 2 h. The reaction

mixture was cooled, diluted with H₂O and the resulting solid was collected by filtration and dried to afford 6 g of **215**.

step 3 - The condensation of **215** and diethyl (4-nitro-benzyl)phosphonate was carried out in accord with the procedure described in step 1 of example 1 to afford 1.8 g of 1-*tert*-butyl-5-iodo-2-methoxy-3-[(*E*)-2-(4-nitro-phenyl)-vinyl]-benzene (**216a**).

step 4 - To a vigorously suspension of **216a** (1.8 g) and DCM (50 mL) was added sequentially zinc dust (6 g) and HOAc (4 mL). The solution was stirred for 10 min then filtered through CELITE and the pad was washed with DCM. The filtrate was stirred over NaHCO₃, washed sequentially with H₂O and brine, dried, filtered and concentrated in vacuo to afford 1.5 g of **216b** as a yellow solid..

Conversion of **216b** into the sulfonamide was carried out in accord with the procedure described in step 3 of example 1 to afford **216c**


step 6 - A microwave vial was charged with **216c** (644 mg, 1.33 mmol), 149 (460 mg, 1.33 mmol), Pd(PPh₃)₄ (150 mg), Na₂CO₃ (425 mg, 4 mmol), dioxane (1.5 ml) and H₂O (1 mL), sealed and irradiated in a microwave synthesizer at 120 °C for 30 min. The reaction was cooled and diluted with EtOAc, washed sequentially with H₂O and brine, dried (Na₂SO₄), filtered and concentrated in vacuo. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (20 to 40% EtOAc) to afford 0.6 g of **218a**.

step 7 - A microwave vial was charged with **218a** (644 mg, 1.33 mmol), Me₄Sn (200 mg, 1.33 mmol), Pd(PPh₃)₄ (100 mg) and THF (5 ml), sealed and irradiated in a microwave synthesizer at 150 °C for 30 min. The resulting solution was cooled, diluted with EtOAc and vigorously stirred with an aq. KF solution. The organic layer was separated, washed with brine, dried (Na₂SO₄), filtered and evaporated. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 20% EtOAc) to afford 80 mg of **218b**.

step 8 - Demethylation of **218b** to afford was carried out in accord with the procedure in step 7 of example 1 to afford 28 mg of **I-43**.

Example 28

2-{(E)-2-[3-*tert*-Butyl-2-methoxy-5-(3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-vinyl}-5-methanesulfonylamino-benzoic acid (**I-9**)



- 5 step 1 – A mixture of **215** (3.58 g, 0.011 mol), methyl 2-methyl-5-nitro-benzoate (2 g, 0.011 mol), DBU (3.8 g, 0.025 mol) and DMSO (30 mL) was heated at 50 °C for 1 h. The reaction mixture was diluted with H₂O and 4N NaOH (10 mL) was added. The mixture was twice extracted with EtOAc. The combined extracts were washed sequentially with 6 N HCl, H₂O, brine, dried (Na₂SO₄), filtered and concentrated *in vacuo* to afford **220** as a yellow solid which
- 10 was dissolved in DMF and K₂CO₃ (13.5 g) and iodomethane (1 mL) were added and the resulting solution stirred at RT for 72 h. The solution was diluted with H₂O and extracted with EtOAc. The organic extract was washed with brine, dried (Na₂SO₄), filtered and concentrated *in vacuo* to afford 3.8 g of **221a**.

- steps 3 & 4 – Reduction of the nitro group (step 3) is carried out in accord with the procedure in
- 15 step 4 of example 27 to afford the amine **221b**. Conversion of **221b** into the sulfonamide was carried out in accord with the procedure described in step 3 of example 1 to afford **221c**.


- step 5 – Palladium-catalyzed coupling of **221c** and *bis*-(pinacolato)diboron was carried out in accord with the procedure described in step 1 of example 19 to afford **222**. The borane ester was isolated by SiO₂ chromatography eluting with an EtOAc/hexane gradient (10 to 40% EtOAc) to
- 20 afford a **222** contaminated with an additional material but which was sufficiently pure to use in the next step.

step 6 & 7 - A microwave vial was charged with **222** (100 mg), 4-chloro-2H-pyridazin-3-one (25 mg), Pd₂(dba)₃ (5 mg), Xantphos (10 mg, CASRN 161265-03-8), Na₂CO₃ (50 mg), *tert*-BuOH and H₂O, sealed and irradiated at 150 °C in a microwave synthesizer for 30 min. The reaction was cooled and worked up. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/DCM gradient (0 to 30% EtOAc) to afford 10 mg of N-(4-{(E)-2-[3-*tert*-butyl-2-methoxy-5-(3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide. The ester was saponified with LiOH in aqueous MeOH at 60 °C for 1 h, cooled and acidified with 6N HCl. The resulting precipitate was filtered and dried in a vacuum oven to afford 6 mg of **I-9**.

10

Example 29

N-(4-{(E)-2-[3-*tert*-Butyl-2-methoxy-5-(1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide (**I-8**)



step 1 – Palladium catalyzed condensation of **84a** and **137** was carried out in accord with the procedure described example 14 to afford **224**. The crude product was purified by recrystallization from THF/hexane.

step 2 – A suspension of **224** (0.30 g) and POCl₃ (6 mL) was heated at 110 °C for 12.5 h. The solution was cooled to RT and poured into ice/H₂O and stirred which resulted in the formation of a yellow precipitate. The solid was filtered, dissolved in EtOAc, washed with brine, dried

(Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 25% EtOAc over 45 min) to afford **226a**.

step 3 – A solution of **226a** (0.74 g, 1.62 mmol) NaOMe (0.34 g), MeOH (20 mL) and MeCN (5 mL) was stirred at RT for 72 h. The resulting solution was partitioned between EtOAc and H₂O. The organic extracts were washed with brine, dried (Na₂SO₄), filtered and evaporated to afford 0.72 g of **226b** which was used without additional purification.

step 4 – A solution of **226b** (0.112 g, 0.224 mmol), iodomethane (0.22 mL) and DCM (0.3 mL) was stirred at RT for 39 h. The volatile solvents were removed *in vacuo* and the crude product purified on a preparative SiO₂ TLC plate developed with 5% MeOH/DCM to afford 0.20 g of **228a** as a yellow solid.


step 5 – Reduction of **228a** to **228b** was carried out with iron powder in accord with the procedure described in step 5 of example 15.

step 6 - Sulfonylation of **228b** to afford **228c** was carried out in accord with the procedure described in step 5 of example 2.

step 7 – Demethylation of **228c** to afford **I-8** was carried out in accord with the procedure described in step 8 of example 2. The crude product was purified on a preparative TLC plate developed with 5% MeOH/DCM to afford the title compound as a yellow powder.

Example 30

N-(4-{(E)-2-[3-*tert*-Butyl-5-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-phenyl]-vinyl}-3-fluoro-phenyl)-methanesulfonamide (**I-7**)



-88-

step 1 – A mixture of **230** (13.35 g, 57 mmol) and triethyl phosphite (9.8 mL, 57.0 mmol) was heated to 150 °C for 3 h. The mixture was cooled and purified by SiO₂ chromatography to afford 12.4 g of **232** (containing 15% of an impurity).

step 2 – Condensation of **232** and **28** was carried out in accord with the procedure in step 1 of example 1 to afford **234a**. The product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 5% EtOAc).


step 3 – Reduction of **234a** to **234b** was carried out with iron powder in accord with the procedure described in step 5 of example 15.

step 4 - Sulfonylation of **234b** to afford **234c** was carried out in accord with the procedure described in step 5 of example 2.

step 5 – A microwave vial was charged with **234c** (136.8 mg, 0.3 mmol), **137** (56.2 mg, 0.36 mmol), Pd(PPh₃)₄ (34.7 mg, 0.03 mmol), Na₂CO₃ (79.5 mg, 0.75 mmol), MeOH (2 mL), DCM (1 mL) and DMF (1 mL), purged with Argon for 5 min, sealed and irradiated in a microwave synthesizer at 115 °C for 1h. The reaction mixture was cooled, filtered through CELITE, the filtrate partitioned between EtOAc and brine. The organic layer was washed with brine, water, dried (Na₂SO₄), filtered and concentrated. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (50 to 100% EtOAc) to afford 77 mg of **I-7** as a white solid.

Example 31

N-(4-{{(E)-2-[5-(2,4-Dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-3-(2,2,2-trifluoroethyl)-phenyl]-vinyl}-phenyl)-methanesulfonamide (**I-38**)



- 5 **step 1** – A mixture of **236** (2.10 g, 11.922 mmol, CASRN 440659-12-1), MgCl₂ (1.70 g, 17.88 mmol), paraformaldehyde (2.5 g, 83.45 mmol), TEA (6.7 mL, 47.69 mmol) and THF was heated at 60 °C overnight. The mixture was cooled and 2N HCl was added. The aqueous solution was extracted with EtOAc. The combined extracts were washed with brine, dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient to afford 1.678 g of **238a** as oil that solidified on standing.
- 10

- step 2** – To a solution of **238a** (1.678 g, 8.219 mmol) and HOAc (8.2 mL) at RT was added dropwise Br₂ (0.844 mL, 16.439 mmol). The reaction mixture was stirred at RT for 72 h. The mixture was diluted with DCM and 10% Na₂S₂O₃ was added and the mixture stirred for several min. The organic layer was washed with sat'd. aq. NaHCO₃, dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by SiO₂ chromatography eluting with an EtOAc/hexane gradient (0 to 10% EtOAc) to afford 1.845 g of **238b** as a yellow solid.
- 15

step 3 - O-methylation of **238b** was carried out in accord with the procedure described in step 9 of example 18. The crude product was purified by SiO₂ chromatography eluting with 10% EtOAc/hexane to afford **239**.

-90-

step 4 - Condensation of **239** with diethyl (4-nitro-benzyl)-phosphonate (step 4) was carried out in accord with the procedures in step 1 of example 1.

step 5 - Palladium-catalyzed coupling of **240c** (0.16 g, 0.364 mmol) and 137 (0.085 g, 0.546 mmol) was carried out in accord with the procedure described in example 14. The crude product
5 was purified by SiO₂ chromatography eluting with 10% MeOH/DCM to afford **242a**.

step 6 - Reduction of the nitro moiety was carried out with iron in accord with the procedure in step 5 of example 15 and the crude product was purified by column chromatography.

step 7 - Sulfonylation of the amine was carried out in accord with the procedure described in step 3 of example 1 to afford **I-38**. The crude product was purified by HPLC.

10

Example 32

HCV NS5B RNA Polymerase Activity

The enzymatic activity of HCV polymerase (NS5B570n-Con1) was measured as the incorporation of radiolabeled nucleotide monophosphates into acid insoluble RNA products. Unincorporated radiolabeled substrate was removed by filtration and scintillant was added to the
15 washed and dried filter plate containing radiolabeled RNA product. The amount of RNA product generated by NS5B570n-Con1 at the end of the reaction was directly proportional to the amount of light emitted by the scintillant.

The HCV polymerase used in the enzymatic activity assay is a 21 amino acid C-terminal deletion of full-length HCV polymerase derived from HCV Con1 strain, genotype 1b (GenBank
20 accession number AJ242654) (NS5B570n-Con1). The NS5B570n-Con1 was sub-cloned downstream to the T7 promoter of the plasmid expression construct pET17b and transformed into E. coli strain BL21(DE3) pLysS for protein expression. A single colony was used to start an inoculum for a 10 L culture in LB media supplemented with 100 µg/mL ampicillin at 37° C. Protein expression was induced by the addition of 0.25 mM isopropyl-β-D-thiogalactopyranoside
25 (IPTG) when the optical density of the culture at 600 nM was 0.8. Induction of protein expression was carried out at 30° C for 16 h after which the cells were harvested by centrifugation. NS5B570n-Con1 was purified to homogeneity using a three-column purification protocol including subsequent column chromatography on Ni-NTA, SP-Sepharose HP and Superdex 75 resins.

Enzymatic reactions in the presence of cIRES RNA template (see section 0004) contained 20 nM cIRES RNA, 20 nM NS5B570n-Con1 enzyme, 0.5 μ Ci of tritiated UTP (Perkin Elmer catalog no. TRK-412; specific activity: 30 to 60 Ci/mmol;), 1 μ M each ATP, CTP, and GTP, 40 mM Tris-HCl pH 8.0, 40 mM NaCl, 4 mM DTT (dithiothreitol), 4 mM MgCl₂, 5 μ l of compound serial diluted in DMSO, and nuclease-free water to a final reaction volume of 50 μ l. Enzymatic reactions in the presence of poly A RNA template (see section 0004) contained 20 nM Poly A:oligo(rU)₁₆ premixed (see section 0004), 20 nM NS5B570n-Con1 enzyme, 1 μ Ci of tritiated UTP (Perkin Elmer catalog no. TRK-412; specific activity: 30 to 60 Ci/mmol), 40 mM Tris-HCl pH 8.0, 40 mM NaCl, 4 mM DTT (dithiothreitol), 4 mM MgCl₂, 5 μ l of compound serial diluted in DMSO, and nuclease-free water to a final reaction volume of 50 μ l. Reaction mixtures were assembled in 96-well filter plates (cat # MADVN0B, Millipore Co.) and incubated for 2 h at 30° C. Reactions were stopped by addition of 10% final (v/v) trichloroacetic acid and incubated for 40 min at 4° C. Reactions were filtered, washed with 8 reaction volumes of 10% (v/v) trichloroacetic acid, 4 reaction volumes of 70% (v/v) ethanol, air dried, and 25 μ l of scintillant (Microscint 20, Perkin-Elmer) was added to each reaction well.

Two RNA templates were used to assay compounds described herein. The cIRES RNA template was 377nucleotide long and consisted of a partial complementary sequence (36 nucleotides) of the core protein, followed by 341 nucleotide of the complementary sequence of the internal ribosome entry site. The poly A RNA template (GE Amersham catalog number 27-4110) was a homopolymeric RNA pre-annealed to a oligo(rU)₁₆ primer at a molar ratio of 3-to-1 (primer-template).

The amount of light emitted from the scintillant was converted to counts per minute (CPM) on a Topcount® plate reader (Perkin-Elmer, Energy Range: Low, Efficiency Mode: Normal, Count Time: 1 min, Background Subtract: none, Cross talk reduction: Off).

Data was analyzed in Excel® (Microsoft®) and ActivityBase® (idbs®). The reaction in the absence of enzyme was used to determine the background signal, which was subtracted from the enzymatic reactions. Positive control reactions were performed in the absence of compound, from which the background corrected activity was set as 100% polymerase activity. All data was expressed as a percentage of the positive control. The compound concentration at which the enzyme-catalyzed rate of RNA synthesis was reduced by 50 % (IC₅₀) was calculated by fitting

-92-

$$Y = \% \text{ Min} + \frac{(\% \text{ Max} - \% \text{ Min})}{\left[1 + \frac{X}{(\text{IC}_{50})^S} \right]} \quad (\text{i})$$

equation (i) to the data where “Y” corresponds to the relative enzyme activity (in %), “%Min” is the residual relative activity at saturating compound concentration, “%Max” is the relative maximum enzymatic activity, “X” corresponds to the compound concentration, and “S” is the Hill coefficient (or slope).

Example 33

HCV Replicon assay

This assay measures the ability of the compounds of formula I to inhibit HCV RNA replication, and therefore their potential utility for the treatment of HCV infections. The assay utilizes a reporter as a simple readout for intracellular HCV replicon RNA level. The Renilla luciferase gene was introduced into the first open reading frame of a genotype 1b replicon construct NK5.1 (N. Krieger et al., *J. Virol.* **2001** 75(10):4614), immediately after the internal ribosome entry site (IRES) sequence, and fused with the neomycin phosphotransferase (NPTII) gene via a self-cleavage peptide 2A from foot and mouth disease virus (M.D. Ryan & J. Drew, *EMBO* **1994** 13(4):928-933). After in vitro transcription the RNA was electroporated into human hepatoma Huh7 cells, and G418-resistant colonies were isolated and expanded. Stably selected cell line 2209-23 contains replicative HCV subgenomic RNA, and the activity of Renilla luciferase expressed by the replicon reflects its RNA level in the cells. The assay was carried out in duplicate plates, one in opaque white and one in transparent, in order to measure the anti-viral activity and cytotoxicity of a chemical compound in parallel ensuring the observed activity is not due to decreased cell proliferation or due to cell death.

HCV replicon cells (2209-23), which express *Renilla luciferase* reporter, were cultured in Dulbecco's MEM (Invitrogen cat no. 10569-010) with 5% fetal bovine serum (FBS, Invitrogen cat. no. 10082-147) and plated onto a 96-well plate at 5000 cells per well, and incubated overnight. Twenty-four hours later, different dilutions of chemical compounds in the growth medium were added to the cells, which were then further incubated at 37°C for three days. At the end of the incubation time, the cells in white plates were harvested and luciferase activity was measured by using the *R. luciferase* Assay system (Promega cat no. E2820). All the reagents described in the following paragraph were included in the manufacturer's kit, and the manufacturer's instructions were followed for preparations of the reagents. The cells were

-93-

washed once with 100 μ L of phosphate buffered saline (pH 7.0) (PBS) per well and lysed with 20 μ L of 1x *R. luciferase* Assay lysis buffer prior to incubation at room temperature for 20 min. The plate was then inserted into the Centro LB 960 microplate luminometer (Berthold Technologies), and 100 μ L of *R. luciferase* Assay buffer was injected into each well and the

5 signal measured using a 2-second delay, 2-second measurement program. IC₅₀, the concentration of the drug required for reducing replicon level by 50% in relation to the untreated cell control value, can be calculated from the plot of percentage reduction of the luciferase activity vs. drug concentration as described above.

WST-1 reagent from Roche Diagnostic (cat no. 1644807) was used for the cytotoxicity assay.

- 10 Ten microliter of WST-1 reagent was added to each well of the transparent plates including wells that contain media alone as blanks. Cells were then incubated for 2 h at 37° C, and the OD value was measured using the MRX Revelation microtiter plate reader (Lab System) at 450 nm (reference filter at 650 nm). Again CC₅₀, the concentration of the drug required for reducing cell proliferation by 50% in relation to the untreated cell control value, can be calculated from the
- 15 plot of percentage reduction of the WST-1 value vs. drug concentration as described above.

TABLE II

Compound Number	HCV Replicon Activity	Cytotoxic Activity
	IC ₅₀ (μ M)	CC ₅₀ (μ M)
I-1	0.112	24.2
I-4	0.347	--
I-9	0.071	--
I-13	0.001	--
I-21	0.113	
I-22	0.025	23.2
I-24	0.04	4.7

Example 34

Pharmaceutical compositions of the subject Compounds for administration via several routes were prepared as described in this Example.

-94-

Composition for Oral Administration (A)

Ingredient	% wt./wt.
Active ingredient	20.0%
Lactose	79.5%
Magnesium stearate	0.5%

The ingredients are mixed and dispensed into capsules containing about 100 mg each; one capsule would approximate a total daily dosage.

5

Composition for Oral Administration (B)

Ingredient	% wt./wt.
Active ingredient	20.0%
Magnesium stearate	0.5%
Crosscarmellose sodium	2.0%
Lactose	76.5%
PVP (polyvinylpyrrolidone)	1.0%

The ingredients are combined and granulated using a solvent such as methanol. The formulation is then dried and formed into tablets (containing about 20 mg of active compound) with an appropriate tablet machine.

10

Composition for Oral Administration (C)

Ingredient	% wt./wt.
Active compound	1.0 g
Fumaric acid	0.5 g
Sodium chloride	2.0 g
Methyl paraben	0.15 g
Propyl paraben	0.05 g
Granulated sugar	25.5 g
Sorbitol (70% solution)	12.85 g
Veegum K (Vanderbilt Co.)	1.0 g
Flavoring	0.035 ml

-95-

Colorings	0.5 mg
Distilled water	q.s. to 100 ml

The ingredients are mixed to form a suspension for oral administration.

Parenteral Formulation (D)

Ingredient	% wt./wt.
Active ingredient	0.25 g
Sodium Chloride	qs to make isotonic
Water for injection to	100 ml

- 5 The active ingredient is dissolved in a portion of the water for injection. A sufficient quantity of sodium chloride is then added with stirring to make the solution isotonic. The solution is made up to weight with the remainder of the water for injection, filtered through a 0.2 micron membrane filter and packaged under sterile conditions.

- 10 The features disclosed in the foregoing description, or the following claims, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for attaining the disclosed result, as appropriate, may, separately, or in any combination of such features, be utilized for realizing the invention in diverse forms thereof.

- 15 The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.

- 20 The patents, published applications, and scientific literature referred to herein establish the knowledge of those skilled in the art and are hereby incorporated by reference in their entirety to the same extent as if each was specifically and individually indicated to be incorporated by reference. Any conflict between any reference cited herein and the specific teachings of this

-96-


specifications shall be resolved in favor of the latter. Likewise, any conflict between an art-understood definition of a word or phrase and a definition of the word or phrase as specifically taught in this specification shall be resolved in favor of the latter.

* * * * *

-97-

Claims

1. A compound according to formula I wherein:



A is a heteroaryl radical selected from the group consisting of 3-oxo-3,4-dihydro-pyrazin-2-yl, 3-oxo-2,3-dihydro-pyridazin-4-yl, 6-oxo-1,6-dihydro-pyrimidin-5-yl, 6-oxo-1,6-dihydro-[1,2,4]triazin-5-yl, 2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl and 4,6-dioxo-1,4,5,6-tetrahydro-pyrimidin-5-yl said heteroaryl being optionally substituted by halogen, C₁₋₆ alkyl, C₁₋₃ haloalkyl, C₁₋₃ dialkylamino or C₁₋₆ alkoxy;

R¹ is hydrogen, hydroxy, C₁₋₃ hydroxyalkyl, COX or cyano;

R² is (a) -[C(R⁶)₂]_p-Ar¹, (b) CR^{7a}=CR^{7b}Ar¹, (c) naphthyl optionally substituted by one to three groups independently selected from the group consisting of C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_nNR^cR^d, cyano, C₁₋₆ alkoxycarbonyl, and carboxyl (d) -NR⁵COAr¹ or (e) CONR⁵Ar¹;

R³ is hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, or halogen, or R³ and R^{4a} together are CH₂-O and together with atoms to which they are attached form a 2,3-dihydrobenzofuran;

R^{4a}, R^{4b} and R^{4c} (i) when taken independently are selected independently from C₁₋₃ alkyl, C₁₋₂ alkoxy, C₁₋₂ fluoroalkyl, hydroxy or halogen or (ii) when taken together, R^{4a} and R^{4b} together are C₂₋₄ methylene and R^{4c} is C₁₋₃ alkyl, C₁₋₂ alkoxy, C₁₋₂ fluoroalkyl or halogen, or (iii) either R⁸ or R³ and R^{4a} together are CH₂-O and together with atoms to which they are attached for a 2,3-dihydro-benzofuran and R^{4b} and R^{4c} are C₁₋₃ alkyl, or (iv) R^{4a} and R^{4b} together are ethylene and R^{4c} is hydrogen, or (v) R^{4a}, R^{4b} and R^{4c} together with the carbon to which they are attached are C₁₋₆ fluoroalkyl;

R⁸ is hydrogen, fluorine or R⁸ and R^{4a} together are CH₂-O and together with atoms to which they are attached form a 2,3-dihydrobenzofuran;

R^5 is hydrogen or C_{1-6} alkyl;

R^6 is independently in each occurrence hydrogen, C_{1-6} alkyl, carboxy, C_{1-6} alkoxy, carbonyl or C_{1-6} hydroxyalkyl;

R^{7a} and R^{7b} are independently hydrogen or C_{1-6} alkyl;

5 Ar^1 is phenyl or pyridinyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, halogen, $(CH_2)_nNR^cR^d$, cyano, C_{1-6} alkoxy, carbonyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl and carboxyl;

10 R^c and R^d are independently in hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} acyl, C_{1-6} sulfonyl, sulfamoyl, C_{1-3} alkylsulfamoyl, C_{1-3} dialkylsulfamoyl, carbamoyl, C_{1-3} alkylcarbamoyl, C_{1-3} dialkylcarbamoyl;

X is OH, C_{1-6} alkoxy or NR^eR^f ;

R^e and R^f are independently hydrogen or C_{1-6} alkyl;

n is zero or 1;

15 p is zero to three; or,

a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein A is 3-oxo-pyridazin-2,3-dihydro-4-yl.

3. A compound according to claim 2 wherein:

R^1 is hydrogen or hydroxy;

20 R^2 is (a) $-[C(R^6)_2]_p-Ar^1$, (b) $CR^{7a}=CR^{7b}Ar^1$ or (c) $-NR^5COAr^1$;

R^{4a} , R^{4b} and R^{4c} are independently C_{1-3} alkyl;

R^6 , R^{7a} and R^{7b} are hydrogen; and,

25 Ar^1 is phenyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, halogen, $(CH_2)_nNR^cR^d$.

4. A compound according to claim 3 wherein R^1 is hydrogen and R^2 is $R^{7a}CH=CR^{7b}Ar^1$.

5. A compound according to claim 4 wherein Ar^1 is phenyl substituted at least by $(\text{CH}_2)_n\text{NR}^c\text{R}^d$ wherein R^c is hydrogen or C_{1-3} alkyl and R^d is C_{1-6} alkylsulfonyl.

6. A compound according to claim 2 wherein R^2 is $-\text{NR}^5\text{COAr}^1$, R^5 is hydrogen and Ar^1 is phenyl substituted at least by $(\text{CH}_2)_n\text{NR}^c\text{R}^d$, R^c is hydrogen or C_{1-3} alkyl and R^d is C_{1-6} alkylsulfonyl..

7. A compound according to claim 1 wherein **A** is 3-oxo-3,4-dihydro-pyrazin-2-yl.

8. A compound according to claim 7 wherein:

R^1 is hydrogen or hydroxy;

R^2 is (a) $-\text{C}(\text{R}^6)_2\text{p}-\text{Ar}^1$, (b) $\text{CR}^{7a}=\text{CR}^{7b}\text{Ar}^1$ or (c) $-\text{NR}^5\text{COAr}^1$;

R^{4a} , R^{4b} and R^{4c} are independently C_{1-3} alkyl;

R^6 , R^{7a} and R^{7b} are hydrogen; and,

Ar^1 is phenyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, halogen, $(\text{CH}_2)_n\text{NR}^c\text{R}^d$.

9. A compound according to claim 8 wherein R^1 is hydrogen and R^2 is $\text{R}^{7a}\text{CH}=\text{CR}^{7b}\text{Ar}^1$.

10. A compound according to claim 9 wherein Ar^1 is phenyl substituted at least by $(\text{CH}_2)_n\text{NR}^c\text{R}^d$ wherein R^c is hydrogen or C_{1-3} alkyl and R^d is C_{1-6} alkylsulfonyl.

11. A compound according to claim 1 wherein **A** is optionally substituted 6-oxo-1,6-dihydro-pyrimidin-5-yl.

12. A compound according to claim 11 wherein R^1 is hydrogen or hydroxy; R^2 is (a) $\text{CR}^{7a}=\text{CR}^{7b}\text{Ar}^1$ or (b) $-\text{NR}^5\text{COAr}^1$; R^{4a} , R^{4b} and R^{4c} are independently C_{1-3} alkyl; R^6 , R^{7a} and R^{7b} are hydrogen; and Ar^1 is phenyl or pyridinyl either optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, halogen, $(\text{CH}_2)_n\text{NR}^c\text{R}^d$.

13. A compound according to claim 1 wherein **A** is 6-oxo-1,6-dihydro-[1,2,4]triazin-5-yl.

14. A compound according to claim 13 wherein **R**¹ is hydrogen; **R**² is **CR**^{7a}=**CR**^{7b}**Ar**¹; **R**^{4a}, **R**^{4b} and **R**^{4c} are independently C₁₋₃ alkyl; **R**⁶, **R**^{7a} and **R**^{7b} are hydrogen; and **Ar**¹ is phenyl or pyridinyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_n**NR**^c**R**^d.

15. A compound according to claim 1 wherein **A** is 2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl.

16. A compound according to claim 15 wherein **R**¹ is hydrogen; **R**² is **CR**^{7a}=**CR**^{7b}**Ar**¹; **R**^{4a}, **R**^{4b} and **R**^{4c} are independently C₁₋₃ alkyl; **R**⁶, **R**^{7a} and **R**^{7b} are hydrogen; and **Ar**¹ is phenyl or pyridinyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_n**NR**^c**R**^d.

17. A compound according to claim 1 wherein **A** is 4,6-dioxo-2-methyl-1,4,5,6-tetrahydro-pyrimidin-5-yl.

18. A compound according to claim 17 wherein **R**¹ is hydrogen; **R**² is **CR**^{7a}=**CR**^{7b}**Ar**¹; **R**^{4a}, **R**^{4b} and **R**^{4c} are independently C₁₋₃ alkyl; **R**⁶, **R**^{7a} and **R**^{7b} are hydrogen; and **Ar**¹ is phenyl or pyridinyl optionally independently substituted with one to three substituents selected from the group consisting of hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, halogen, (CH₂)_n**NR**^c**R**^d.

19. A compound according to claim 1 which compound is selected from the group consisting of:

N-(4-{2-[3-*tert*-butyl-2-methoxy-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-ethyl}-phenyl)-methanesulfonamide;

N-(4-{2-[3-*tert*-butyl-2-methoxy-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-ethyl}-phenyl)-acetamide;

N-(4-{2-[3-*tert*-butyl-4-fluoro-2-methoxy-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-ethyl}-phenyl)-methanesulfonamide;

N-[3-*tert*-butyl-2-methoxy-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-4-methanesulfonylamino-benzamide;

N-(4-{2-[5-*tert*-butyl-2-hydroxy-3-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-ethyl}-phenyl)-methanesulfonamide;

N-(4-{(E)-2-[5-*tert*-butyl-2-hydroxy-3-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide;

5 *N*-{(S)-1-[7-*tert*-butyl-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-benzofuran-3-carbonyl]-pyrrolidin-3-ylmethyl}-methanesulfonamide;

N-{4-[7-*tert*-butyl-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-benzofuran-3-carbonyl]-morpholin-2-ylmethyl}-methanesulfonamide;

10 *N*-{1-[7-*tert*-butyl-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-benzofuran-3-carbonyl]-piperidin-3-ylmethyl}-methanesulfonamide;

N-(4-{(E)-2-[3-*tert*-butyl-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide;

N-(4-{(E)-2-[3-*tert*-butyl-2-methoxy-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide;

15 4-(3-*tert*-butyl-5-methyl-phenyl)-2*H*-pyridazin-3-one;

N-(4-{(E)-2-[3-*tert*-butyl-2-methoxy-5-(3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide;

4-[3-*tert*-butyl-4-methoxy-5-((E)-styryl)-phenyl]-2*H*-pyridazin-3-one;

20 *N*-(4-{(E)-2-[3-*tert*-butyl-5-(3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide;

4-(3-*tert*-butyl-4-methoxy-phenyl)-2*H*-pyridazin-3-one;

N-(4-{(E)-2-[3-*tert*-butyl-2-methoxy-5-(6-methyl-3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide;

25 *N*-(4-{(E)-2-[3-*tert*-butyl-5-(5-chloro-3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide;

4-amino-*N*-[3-*tert*-butyl-2-methoxy-5-(3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-benzamide;

N-[3-*tert*-butyl-2-methoxy-5-(3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-4-(2,2,2-trifluoro-ethylamino)-benzamide;

N-(4-{{(E)-2-[3,3-dimethyl-7-(3-oxo-2,3-dihydro-pyridazin-4-yl)-2,3-dihydro-benzofuran-5-yl]-vinyl}-phenyl)-methanesulfonamide;

N-(4-{{(E)-2-[3-*tert*-butyl-2-methoxy-5-(6-oxo-1,6-dihydro-pyrimidin-5-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide;

5 *N*-(4-{{(E)-2-[3,3-dimethyl-7-(3-oxo-3,4-dihydro-pyrazin-2-yl)-2,3-dihydro-benzofuran-5-yl]-vinyl}-phenyl)-methanesulfonamide;

2-{{(E)-2-[5-(2-benzyloxy-6-oxo-1,6-dihydro-pyrimidin-5-yl)-3-*tert*-butyl-2-methoxy-phenyl]-vinyl}-5-methanesulfonylamino-benzoic acid methyl ester;

10 *N*-(4-{{(E)-2-[3-*tert*-butyl-5-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-phenyl]-vinyl}-phenyl)-methanesulfonamide;

N-(4-{{(E)-2-[3-cyclopropyl-2-methoxy-5-(3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide;

N-(4-{{(E)-2-[4-methoxy-3,3-dimethyl-7-(3-oxo-2,3-dihydro-pyridazin-4-yl)-2,3-dihydro-benzofuran-5-yl]-vinyl}-phenyl)-methanesulfonamide;

15 *N*-(4-{{(E)-2-[7-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-4-methoxy-3,3-dimethyl-2,3-dihydro-benzofuran-5-yl]-vinyl}-phenyl)-methanesulfonamide;

N-(6-{{(E)-2-[3-*tert*-butyl-5-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-phenyl]-vinyl}-pyridin-3-yl)-methanesulfonamide;

20 *N*-(4-{{(E)-2-[3-(1-difluoromethyl-cyclopropyl)-5-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-phenyl]-vinyl}-phenyl)-methanesulfonamide;

N-(4-{{(E)-2-[3-(1-difluoromethyl-cyclopropyl)-2-methoxy-5-(3-oxo-3,4-dihydro-pyrazin-2-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide;

N-(4-{{(E)-2-[3-*tert*-butyl-5-(2-chloro-6-oxo-1,6-dihydro-pyrimidin-5-yl)-2-methoxy-phenyl]-vinyl}-phenyl)-methanesulfonamide;

25 *N*-(4-{{(E)-2-[5-(4-benzyloxy-2-dimethylamino-pyrimidin-5-yl)-3-*tert*-butyl-2-methoxy-phenyl]-vinyl}-phenyl)-methanesulfonamide;

N-(4-{{(E)-2-[3-*tert*-butyl-2-methoxy-5-(2-methoxy-6-oxo-1,6-dihydro-pyrimidin-5-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamid;

N-(4-{(E)-2-[5-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-3-trifluoromethyl-phenyl]-vinyl}-phenyl)-methanesulfonamide;

N-(4-{(E)-2-[3-*tert*-butyl-2-methoxy-5-(6-oxo-1,6-dihydro-[1,2,4]triazin-5-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide;

5 *N*-{6-[3-*tert*-butyl-2-methoxy-5-(6-oxo-1,6-dihydro-[1,2,4]triazin-5-yl)-phenyl]-naphthalen-2-yl}-methanesulfonamide;

N-(4-{(E)-2-[5-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-3-(2,2,2-trifluoro-ethyl)-phenyl]-vinyl}-phenyl)-methanesulfonamide;

10 *N*-(4-{(E)-2-[3-*tert*-butyl-2-methoxy-5-(2-methoxy-6-oxo-1,6-dihydro-pyrimidin-5-yl)-phenyl]-vinyl}-3-methoxymethyl-phenyl)-methanesulfonamide;

N-(4-{(E)-2-[5-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methoxy-3-trifluoromethoxy-phenyl]-vinyl}-phenyl)-methanesulfonamide;

N-(4-{(E)-2-[3-*tert*-butyl-5-(4-hydroxy-2-methyl-6-oxo-1,6-dihydro-pyrimidin-5-yl)-2-methoxy-phenyl]-vinyl}-phenyl)-methanesulfonamide;

15 *N*-(4-{(E)-2-[3-*tert*-butyl-2-methoxy-5-(2-methyl-6-oxo-1,6-dihydro-pyrimidin-5-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide;

2-{(E)-2-[3-*tert*-butyl-2-methoxy-5-(3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-vinyl}-5-methanesulfonylamino-benzoic acid; and,

20 *N*-(4-{(E)-2-[3-*tert*-butyl-2-methoxy-5-(1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-phenyl]-vinyl}-phenyl)-methanesulfonamide; or

a pharmaceutically acceptable salt thereof.

20. A compound of formula I according to anyone of claims 1 to 19 for use as an active pharmaceutical substance.

25 21. A compound of formula I according to anyone of claims 1 to 19 for use as an active pharmaceutical substance according to claim 20 in combination with at least one least one immune system modulator and/or at least one antiviral agent that inhibits replication of HCV.

22. A compound of formula I according to anyone of claims 1 to 19 for use as an active pharmaceutical substance according to claim 21 in combination with at least one interferon, a

chemically derivatized interferon, interleukin, tumor necrosis factor or colony stimulating factor.

23. A compound of formula I according to anyone of claims 1 to 19 for use as an active pharmaceutical substance according to claim 22 in combination with at least one antiviral compound selected from the group consisting of a HCV protease inhibitor, another HCV polymerase inhibitor, a HCV helicase inhibitor, a HCV primase inhibitor and a HCV fusion inhibitor.
24. The use of a compound according to anyone of claims 1 to 19 for the manufacture of a medicament useful for the treatment a Hepatitis C Virus (HCV) infection.
25. A medicament comprising a compounds according to anyone of claims 1 to 19 alone or in combination with other antiviral compounds or immunomodulators.
26. A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof, a therapeutically effective quantity of a compound according to claim 1.
27. The method of claim 26 further comprising co-administering at least one immune system modulator and/or at least one antiviral agent that inhibits replication of HCV.
28. The method of claim 27 wherein the immune system modulator is an interferon, a chemically derivatized interferon, interleukin, tumor necrosis factor or colony stimulating factor.
29. The method of claim 28 wherein the antiviral compound is selected from the group consisting of a HCV protease inhibitor, another HCV polymerase inhibitor, a HCV helicase inhibitor, a HCV primase inhibitor and a HCV fusion inhibitor.
30. A method for inhibiting replication of HCV in a cell by delivering a compound according to claim 1.
31. A composition comprising a compound according to claim 1 admixed with at least one carrier, diluent or excipient.